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Abstract
In the human body there are tissues with limited regenerative potential, raising the need for
cell-based regenerative therapies. The main objective of this thesis was to examine how
tissue-specific extracellular matrix (ECM) affects the differentiation of human adiposederived stem/stromal cells (ASCs). The effects of incorporating milled, decellularized
adipose (DAT) or cartilage (DCT) ECM particles on ASC lineage-specific differentiation in
3-D cell aggregate cultures were explored. The results demonstrated that the addition of
ECM improved differentiation for both adipogenesis and chondrogenesis. Analysis of
adipogenic gene and protein expression indicated enhanced differentiation in the DAT+ASC
aggregates relative to the DCT+ASC and ASC-alone groups at 14 days. Additionally,
chondrogenic studies showed that incorporating DCT had a positive effect on collagen II
deposition and late chondrogenic marker expression at 28 days when compared to
DAT+ASC or ASC-alone groups. Overall, these findings support the further investigation of
ECM as a cell-instructive platform for ASC differentiation.
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chondrogenesis, differentiation, cell-ECM aggregates, cell-based therapy, tissue engineering,
regenerative medicine.
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Chapter 1
1

Introduction

In the emerging field of tissue engineering, many strategies have been developed to overcome
obstacles related to tissue loss associated with injury or disease. Tissues with limited
regeneration potential require stimulation to assist with the repair process in order to prevent scar
tissue formation and promote recovery of function. Many studies exploit the use of bioactive
materials and various cell types to stimulate in situ tissue formation. The concept that stem cell
fate is regulated by the extracellular environment in vivo is well founded in research [1][2].
Recent studies suggest that cellular behavior of stem/stromal cells is mediated in part though
biochemical and biomechanical interactions with the extracellular matrix (ECM), as well as
through other environmental cues (e.g. oxygen tension) and signaling with surrounding cells
[3][4].
The ECM is a complex 3-dimensional network of proteins, proteoglycans, and glycoproteins that
are tissue-specific in structure and composition [3]. The ECM is known to influence cellular
responses such as cell survival, development, shape, and migration through interactions with
adhesion molecules, binding proteins and various enzymes [4][5]. Physical and biomechanical
cues such as matrix architecture and surface chemistry also play an important role in mediating
cellular functions [6]. A large area of tissue engineering and cell-based therapy research is
focused on designing novel scaffolds and biomaterials to mimic the ‘tissue-specific niche’ and
simulate the biomechanical and biochemical cues present in vivo in order to stimulate
regeneration [5][7][8].
For the development of cellular therapies, adipose tissue represents an attractive source of adult
mesenchymal stem/stromal cells (MSCs) [9]. Adipose-derived stem/stromal cells (ASCs) can be
isolated from the stromal vascular fraction (SVF) of digested adipose tissue using established
procedures. The stem/stromal population is selected through serial passaging of the tissue culture
polystyrene (TCPS)-adherent cell population [10]. ASCs are a promising cell source for
regenerative therapies due to their relative abundance and ease of access when compared with
other MSC sources, such as bone marrow-derived MSCs [9]. Further, ASCs are a heterogeneous
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cell population that includes multipotent adult stem cells, capable of differentiating along the
adipogenic, chondrogenic, and osteogenic lineages, as well as displaying cell surface markers of
the neuronal, endothelial, and hematopoietic lineages [11][12]. ASCs may be incorporated into
scaffolds, where they assist in modulating the cell niche by stimulating the recruitment and
differentiation of host cells through paracrine signaling [10].

1.1

Project Motivation

The ECM is a key component of the tissue-specific natural microenvironment for cells.
Therefore ECM-derived biomaterials are of interest as stem cell delivery vehicles, to improve
cell attachment and survival in vivo [13][14]. The heterogeneity of the ECM composition within
various tissues provides a rationale for applying a tissue-specific approach to bio-scaffold design.
The selection of naturally derived, tissue-specific scaffolds comprised of ECM as a platform for
tissue regeneration is well supported, as it is recognized that cells exchange signals with both
neighboring cells and the surrounding matrix [15][2][16]. An ideal scaffold should mimic the
properties of the native tissue, supporting the rationale for the use of tissue-specific scaffolds.
Many approaches target tissue decellularization as a method of obtaining tissue-specific ECM
from sources such as heart, adipose tissue, cartilage, bone, kidney and lung [9], [17]–[21].
However, limited research has been done to date to compare the effects of tissue-specific ECM
on the lineage-specific differentiation of MSCs [22][18][9].

1.2

Project Rationale

To study the effects of tissue-specific ECM on the adipogenic and chondrogenic differentiation
of human ASCs in vitro, culture conditions must allow for adipogenesis and chondrogenesis to
occur in their preferred environment, which is a 3-dimensional (3-D) culture with high cell
density [23][24][25]. A high cell density is often achieved by culturing ASCs clustered in an
aggregate, often referred to as a pellet culture. Incorporating decellularized ECM sourced from
adipose tissue or cartilage into the cell aggregate cultures will give insight into the potential
importance of using tissue-specific ECM to guide differentiation and/or to act as a natural
scaffold for the regeneration of adipose or cartilage tissue. For this reason, decellularized adipose
tissue (DAT) and decellularized cartilage tissue (DCT) were lyophilized, milled, and
incorporated into 3-D aggregates fabricated by centrifuging a suspension of ASCs and ECM
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particles. In vitro cell culture studies were conducted to explore adipogenesis and
chondrogenesis of ASCs in the cell-ECM aggregates. The level of adipogenic and chondrogenic
differentiation within the various aggregates was assessed in both proliferation medium and
differentiation medium to examine the potential inductive effects of the ECM on ASC
differentiation. ASCs were also cultured in cell aggregate cultures without ECM as a control.

1.3

Hypothesis

With support from the literature that tissue-specific ECM has the ability to influence cellular
behaviors, it was hypothesized that the ECM will stimulate ASCs to differentiate towards the
lineage specific to that of the native tissue. Therefore, cells cultured with DAT particles will
demonstrate an increased tendency for differentiation towards the adipogenic lineage and the
ECM will have an inductive effective on adipogenic differentiation under proliferation
conditions. Similarly, ASCs cultured with DCT particles will be induced towards the
chondrogenic pathway. It was expected that differentiation levels will be higher in all aggregates
containing ECM, and that differentiation towards the adipogenic lineage will be highest in the
samples combining DAT with adipogenic medium. Likewise, chondrogenic differentiation was
expected to be highest when ASCs were cultured with DCT in chondrogenic medium.

1.4

Specific Objectives

The objectives of this Master’s project were:
1) To establish methods for decellularizing porcine auricular cartilage based on existing
decellularization protocols in the literature.
2) To refine protocols for cryo-milling the DAT and DCT, and to characterize the particles
using SEM and dynamic light scattering.
3) To conduct in vitro cell culture studies to investigate adipogenesis and chondrogenesis in

cell aggregates comprised of (i) ASCs and DAT (ii) ASCs and DCT, and (iii) ASCs
alone, cultured in both differentiation and proliferation media.
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Chapter 2
2

Literature Review

2.1

Adipose-derived Stem/Stromal Cells (ASCs)

Research conducted by Friedenstein et al. identified some of the first reported evidence of tissue
culture polystyrene (TCPS)-adherent bone marrow-derived mesenchymal stem/stromal cells
(BMSCs) that were capable of expansion and differentiation towards osteogenic lineages [26].
Further examination led to the identification of stem/stromal cells within other adult tissues, and
since this time mesenchymal stem/stromal cells (MSCs) have been discovered within many
human tissues [27]–[29]. This work revolutionized modern cell therapy strategies as MSCs
became more readily available, and could be expanded in culture and differentiated towards
multiple lineages [30]. Adipose-derived stem/stromal cells (ASCs) are attractive as a cell source
due to their relative abundance, the ease of access to adipose tissue (fat) with minimal discomfort
to patients, and the larger cell yield when compared to BMSC populations [29]. While BMSCs
have been studied extensively, limitations to using this cell type include low yields (1 BMSC in
every 3.4 x 104 bone marrow nucleated cell population) and painful collection procedures [31]. It
is for these reasons that ASCs are being extensively researched in the field of regenerative cell
therapies.
Another benefit of ASCs is the potential to be an autologous stem/stromal cell source for
patients, as the cells are easily obtained from subcutaneous fat stores within the body. Cellular
procurement may be accomplished through minimally invasive procedures such as lipoaspiration
[29] or from excess tissues collected during elective breast or abdominal reduction surgeries
[32]. There are varying methods of ASC isolation, but common protocols involve enzymatic
digestion and centrifugation steps to yield the stromal vascular fraction (SVF). Current views of
ASCs suggest that they co-exist with resident endothelial cells and pericytes within the
perivascular niche in vivo. After isolation, the SVF contains a heterogeneous mixture of
endothelial progenitor cells, pericytes, fibroblasts, blood cells, smooth muscle cells,
macrophages, pre-adipocytes, and MSCs [33]–[35]. Expansion of the heterogeneous SVF aids in
the selection of adherent cell populations to yield a purer ASC culture. Donor variability,
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isolation procedures, growth conditions, and sites of tissue harvesting have been noted as
potential reasons for differences seen within varying ASC populations [36]–[38].
Recent studies found that an increased donor age, increased body mass index (BMI), and reduced
donor health have been linked to decreased proliferation and differentiation capacities and an
increase in cell senescence markers [39]–[41]. Interestingly, donor depot has also been linked to
differences in ASC characteristics [42]. Studies by Schipper et al. found that the upper arm and
medial thigh depots consistently yielded ASCs with a greater proliferation and differentiation
capacity when compared to the depots of the abdomen or trochanter [42]. Russo et al. reported
that adipogenesis was enhanced in ASCs isolated from subcutaneous, pericardial, and thymic
remnant adipose tissue, while osteogenic differentiation levels were upregulated in ASCs
sourced from the omentum [43]. Other potential differences have also been noted between male
and female donors, however more research is needed to confirm these findings [43], [44]. These
findings highlight the need for larger studies to assess significant differences between donor
gender, depot site, age, and BMI and the effect these factors may have on ASC proliferation and
differentiation capacity and ASC immunophenotypes.

2.1.1 ASCs in Regenerative Tissue Engineering
According to Gimble et al., ASCs retain the ability to give rise to genetically identical daughter
cells through the process of mitotic division [38]. ASCs are also capable of differentiation
towards cells of the mesodermal lineage, including adipocyte, chondrocyte, osteoblast, myocyte,
and peripheral nerve lineages [29], [45]. Based on yields obtained from isolations, expected
cellular demands for therapeutic applications can require approximately 109 stem cells [46].
ASCs have the potential to meet that need, making them promising sources for musculoskeletal
research applications. Comparatively, reports on ASC isolations suggest that cell yields can
reach 40 times more than BMSCs [29], [47], [48].
ASCs have the ability to be cultured in various conditions such as 2-D and 3-D cultures, under
normoxic and hypoxic conditions, static and dynamic cultures, and under different media
formulations [45]. This is beneficial from a culturing perspective as methods can be altered to
examine cellular behavior from a multitude of perspectives in culture. Due to the ability of ASCs
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to be cultured under various conditions, cultures may be tailored to conditions seen in a specific
tissue of interest in vivo, including in diseased states.
ASCs are also capable of secreting paracrine factors that can modulate wound healing [49]. A
variety of growth factors such as platelet-derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), as well as cytokines such as interleukin-10 (IL10) and prostaglandin E2
(PGE2) have been shown to be secreted by ASCs within wound healing sites [50]–[52].
Evidence also suggests that ASCs are capable of modulating macrophage behavior and recruiting
cells to promote tissue remodeling [53]. Transplantation of ASCs in vivo demonstrates minimal
evidence of immune rejection and as a result, allogeneic ASCs may hold potential for use in cell
therapy applications [46].

2.1.2 Immunophenotype of ASCs
The International Society for Cellular Therapy (ISCT) and the International Federation for
Adipose Therapeutics and Science (IFATS) have defined a set of parameters with the intention
of characterizing ASCs. The following criteria were proposed for the characterization of ASCs:
(1) plastic-adherent, (2) express the standard immunophenotypic profile (Table 2.1), and (3)
maintain multipotency towards the adipogenic, osteogenic, and chondrogenic lineages [54].
ISCT and IFATS suggest that immunophenotype analysis should include at least two primary
positive markers, one secondary positive marker, two primary negative markers, and one
secondary negative marker when characterizing ASCs [54]. Positive expression of primary
markers should be greater than 80% but less than 2% for primary negative markers. Additionally,
cell viability should be greater than 90% [54]. It is worth noting that some discrepancies have
been published in terms of expression levels of some markers between culture conditions and
passage number, highlighting the need for guidelines for characterizing ASC populations, as well
as standardization of isolation and culture methods. In addition, studies have noted that
immunophenotypes of ASCs may be altered in 2-D cultures when compared to cells found in
vivo or when cultured in 3-D cultures [46].
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Table 2.1 ASC Immunophenotype
Marker type

Antigen

Primary positive (>80%)

CD90 (Thy-1)
CD105 (endoglin)
CD73 (ecto-5’-nucleotidase)
CD44 (hyaluronic acid receptor)
CD29 (β1-integrin)
CD13 (aminopeptidase-N)
CD34 (progenitor associated marker)*
CD146 (melanoma cell adhesion molecule (MCAM))*
CD10 (nephrilysin)
CD26 (dipeptidyl peptidase-4)
CD48d (α4-integrin)*
CD49e (α5-integrin)
CD36 (fatty acid translocase)
CD31 (platelet endothelial cell adhesion molecule (PECAM))
CD45 (leukocyte-common antigen-antigen D related)
CD3 (T-cell co-receptor)
CD11b (α6-integrin)
CD49F (αM-integrin)
CD106 (vascular cell adhesion protein 1 (VCAM-1))

Secondary positive

Primary negative (<2%)
Secondary negative

*Variable levels of expression

2.1.3 Adipogenesis
It is known that ASCs are capable of differentiating along multiple pathways, including the
adipogenic pathway [29]. In general, ASCs undergoing adipogenesis prefer close cell-cell
contact, suggesting that a high cell density is preferred prior to differentiation towards this
lineage. ASCs have been shown to differentiate both on 2-D TCPS and on 3-D scaffolding
materials [32]. Glucocorticoid agonists such as hydrocortisone and dexamethasone (DEX)
initiate the induction of ASCs toward the adipogenic pathway (Figure 2.1) [55]. Presence of
hydrocortisone and DEX, along with supra-physiological insulin concentrations, initiate a
signaling cascade [56], [57]. This in turn activates receptors in pre-adipocytes to stimulate the
activation of early transcription factors CCAAT/enhancer-binding protein-β (C/EBPβ) and
CCAAT/enhancer-binding protein-δ (C/EBPδ) [58]. This causes the upregulation of the primary
transcription factors peroxisome proliferator activated receptor-ϒ (PPARϒ) and
CCAAT/enhancer-binding protein-α (C/EBPα) [55], [57]. Cell proliferation is inhibited by the
activation of C/EBPα while sensitivity to insulin is maintained. A positive feedback loop ensues
7

between PPARϒ and C/EBPα to maintain increased expression as the cells accumulate lipid
during maturation and move closer to terminal differentiation [59], [60]. Adipocyte-specific
genes such as lipoprotein lipase (LPL), glucose transporter-4 (GLUT4), glycerol-3-phosphate
dehydrogenase (GPDH) and insulin receptors are all upregulated, driving the cells to further
maturation and lipid accumulation [55].

Figure 2.1 Transcriptional control of adipogenesis.
There is a delicate balance of factors that mediate adipogenesis along the transcriptional
signaling cascade. Fatty acids and prostaglandins act as ligands or precursor ligands for PPARϒ
or may help to induce the adipogenic factors C/EBPβ and C/EBPδ [61]–[63]. Glucocorticoids
also promote adipogenesis through activating C/EBPδ and PPARϒ expression [64], [65].
Nuclear co-activated receptors, like PPAR binding protein, work through PPARϒ to promote
adipogenesis [60]. Insulin-like growth factor-I receptors (IGF-IRs) also function to increase
insulin sensitivity of the cells, driving maturation. Conversely, factors such as wingless-related
integration site (Wnt) signaling, transforming growth factor-β (TGF-β), tumor necrosis factor-α
(TNF-α), and interleukins (IL-1, IL-6, IL-11) inhibit adipogenesis through inhibition of PPARϒ
and CEBPα [55], [57], [66]. Upregulation of adipogenesis in vitro often includes the addition of
supplements such as insulin, DEX, hydrocortisone, troglitazone, and 3-isobutyl-1methylxanthine (IBMX) to serum free media [67], [68].
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2.1.4 Chondrogenesis
ASCs have the ability to differentiate towards the chondrogenic lineage, however, this cannot be
accomplished in 2-D on TCPS. The cells require the high cell density and close cell-cell contact
that can only be accomplished in 3-D cultures [69], [70]. It is for this reason that pellet cultures
are often used during chondrogenesis [71]. This culture format mimics the mesenchymal
condensation process that occurs during chondrogenesis in vivo and allows the cells to initiate
differentiation towards the chondrogenic pathways [72].
Sex-determining region Y-related high motility group box 9 (SOX9) is an important transcription
factor in chondrogenesis [73]. Transcription of SOX5 and SOX6 is induced by SOX9, which act
in turn to enhance SOX9 activity and maintain chondrogenic phenotypes, preventing
hypertrophy [74]. SOX9 induces chondrogenesis by upregulating cartilage-matrix specific genes
to help maintain pre-chondrocyte phenotypes [75]. Chondrogenic factors such as TGF-β and
bone morphogenic proteins (BMPs) are key to initializing the chondrogenic signaling cascade
that leads to the condensation process [76]–[79]. ASCs begin to differentiate into chondroblasts
following condensation. In this stage, the cells are highly proliferative and begin matrix
deposition of collagens II, IX, XI, and aggrecan (Figure 2.2) [78], [80]. Subsequently, cartilage
oligomeric matrix protein (COMP) is upregulated while collagen I is downregulated [71], [72],
[59]. It is for this reason that ratios of collagen II:collagen I are often compared using
immunohistochemistry (IHC) to assess chondrogenesis.
Late stages of chondrogenesis may see chondroblasts become hypertrophic chondrocytes, where
collagen X is upregulated and calcification begins [80]. This signals terminal differentiation of
chondrogenesis and marks the beginning of osteo-chondrogenesis. Runt-related transcription
factor 2 (RUNX2) is upregulated during this time [81]. Since none of this can occur without the
initial condensation process that triggers upregulation of SOX9 and cartilage-specific ECM
synthesis, it can be stated that chondrogenesis is highly dependent not only on transcriptional
control but may be partially controlled by cells responding to signals within their immediate
surroundings, including the ECM [72], [73], [75], [82].
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Figure 2.2 Transcriptional control of chondrogenesis.

2.2

The Extracellular Matrix (ECM)

Tissue loss acquired through disease or trauma poses problems where tissue regeneration is
limited due to scar tissue formation and/or the loss of function in the afflicted area. This loss of
function can impact the health and well-being of the patient. This raises the need for the
development of cell-based therapies for connective tissue loss and is a major area of research in
tissue engineering. In the field of tissue engineering, there is growing evidence to support the
application of cell-based therapies to promote the regeneration of soft connective tissues in order
to restore structure and function following tissue damage [29], [82]. Recent studies have
suggested that the proliferation and differentiation of stem/stromal cells can be mediated through
interactions with the ECM [6], [83]–[85]. Therefore, cell-based approaches that combine
stem/stromal cell-based therapies with biomaterials have become a highly researched field of
study.
Tissues within the body are comprised of cells and an extracellular matrix that is comprised of an
intricate network of proteins and polysaccharides [86]. The macromolecules within the ECM are
locally secreted by the cells and assembled and organized into tissue-specific structures [3], [5],
[87]. There is a dynamic relationship that exists between the cells and the ECM. The ECM is
active in regulating cellular behaviors and processes such as attachment, proliferation, and
survival [88]. Likewise, as the cells within the niche respond to their environment, they secrete
factors that induce alterations or remodeling of their surroundings [88], [89]. For example, cells
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can secrete matrix metalloproteinases (MMPs) that enzymatically degrade the ECM to allow for
cellular migration and release of ECM-bound molecules [90], [91]. This dynamic state highlights
the interdependent relationship of cells and the ECM, supporting the rationale for incorporating
ECM-based biomaterials into therapeutic strategies.
There are two main types of ECM, the basement membrane/basal lamina and connective tissue
ECM [92], [93]. The basal lamina is a thin, highly bioactive structure that is often associated
with various pathologies such as epidermolysis bullosa [94]. Connective tissue ECM is very
important in cell regulation as it provides both structural and chemical cues to the cells [95]. The
cells within a tissue help to create and maintain the integrity of the ECM by constant remodeling
in response to stimuli [96].
The main macromolecules secreted by the cells within the matrix are: (1) fibrous proteins that
include collagen and elastin, (2) glycosaminoglycans (GAGs), (3) proteoglycans, and (4)
glycoproteins [97]. The specificity of the matrix is determined by the relative amounts of the
different macromolecules within the matrix and the organization of those components to give
tissue-specific structures and functions. Regulation of cellular behavior is achieved by
interactions with cells and the surrounding matrix. Cell surface receptors called integrins bind
cells to the ECM and can trigger a signaling cascade via the cytoskeleton in response to
mechanical stimuli [86]. Functions such as cell shape, survival, proliferation, migration, and
tissue cohesion may be determined, in part, by the ECM [89]. For this reason, it is important to
have an understanding of the components of the cell-secreted ECM. This section will focus on
the main types of macromolecules present in the ECM. The specific structure and composition of
adipose tissue and cartilage ECM will be discussed in detail in Sections 2.4.1 and 2.5.1
respectively.

2.2.1.1

Fibrous Proteins

Fibroblasts synthesize collagens, GAGs, and glycoproteins and are responsible for a large
majority of matrix production and remodeling in many tissues in the body [90]. In adipose tissue,
adipocytes and pre-adipocytes are responsible for the majority of ECM production, however
other cells types such as fibroblasts, vascular cells, and macrophages can be involved in matrix
synthesis and modification [98]–[101]. In comparison, cartilage ECM is deposited mainly by
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chondrocytes [102], [103]. Proteins embedded within the matrix act as sites for cell adhesion and
signaling. Collagen plays a major role within the ECM and is one of the main components that
make up these complex structures [104].
Collagen fibers impart structural integrity, organization, strength and resilience to the ECM and
therefore play an important role in cell attachment, growth and differentiation through receptor
mediated signaling [105]. Collagens are the most abundant fibrous proteins within the interstitial
ECM, comprising 20-40% of total protein within the body. This family of structural and
bioactive proteins functions to regulate cell adhesion, support cellular migration, and direct tissue
development [106]. The right-handed triple helix comprised of three α-chain subunits is a
defining characteristic of collagen (Figure 2.3a) [104]. These α-chain subunits are stabilized by
hydrogen bonds and are each encoded by a unique gene. Within these long polymers, there are
repeated amino acid sequences of (Gly-X-Y) where approximately 30% of the time X is proline
and Y is hydroxyproline [104]. To date, 28 different types of collagen have been identified and
can be classified as either (1) fibrillar, (2) fibril associated collagen with interrupted helices
(FACIT), (3) short chain, (4) basement membrane, or (5) microfibrillar [105]. Each of these
collagen types is associated with unique amino acid sequences and conformational structures that
give individual functions, such as basement membrane collagens like collagen IV [97]. The αchains within collagen IV lack a glycine residue in every third amino acid, allowing the chains to
be covalently crosslinked and assembled into flexible sheet-like structures [105], [104].
The ability of tissues to deform from mechanical stimuli and recoil back to their original state
can be attributed to the properties of the insoluble fibrous protein, elastin (Figure 2.3) [107].
Elastin is comprised of multiple tropoelastin monomers that are crosslinked by lysyl oxidase to
form desmosine residues (Figure 2.3b) [108], [109]. Non polar amino acid residues comprise
much of these monomers, which are rich in proline and lysine [110]. Elastin and collagen are
often in close association, as the stretch of elastin is limited by the tight associations with
collagen fibrils [106].
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Figure 2.3 Representative images of (a) collagen, (b) elastin, (c) fibronectin, and (d)
laminin. Images adapted from Lange Histology and Cell Biology, 2010 [111].

2.2.1.2

Glycosaminoglycans

GAGs are comprised of repeating disaccharide units, where one of the two sugars is always an
amino sugar (N-acetylglucosamine or N-acetylgalactosamine), and the other sugar is usually an
uronic acid (glucuronic or iduronic). These sugars typically contain carboxyl or sulphate groups,
and create an anionic charge [97]. GAGs may be further subcategorized into four main types,
distinguished by the sugars, the linkage of those sugars, and the number and location of the
sulphate groups. The main types of GAGs are: hyaluronan, chondroitin sulphate, heparan
sulphate, keratin sulphate, dermatan sulphate and heparin, which may be found in varying
amounts within different tissues [97], [106]. Hyaluronan is found in skin and load bearing joints,
and chondroitin sulphate is most commonly found in ligaments, tendons, and cartilage [112].
GAGs aid in resisting compressive forces through their negative charges. The highly negative
nature of GAGs attracts ions such as Na+, allowing the matrix to become hydrated [106], [112].
The osmotic pressure created, such as that within the knee joint, allows the tissue to withstand
large compressive forces [97], [113]. For example, hyaluronan is a type of GAG that is found in
load-bearing joints that not only aids in resisting compressive forces, but also contributes to joint
lubrication [97]. With the exception of hyaluronan, GAGs are covalently attached to proteins to
create proteoglycans [97].
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2.2.1.3

Proteoglycans

Proteoglycans consist of polysaccharide chains bound to a protein where at least one of the sugar
side chains is a GAG, thus distinguishing them from glycoproteins [114]. Proteoglycans may
contain more sugars by weight (up to 95%) when compared to glycoproteins, and may have
many long unbranched GAG chains [115], [116]. Proteoglycans are remarkably diverse,
possessing a variety of structures and functions. Aggrecan, for example, is one of the most
important ECM proteins in cartilage that aids in the load distributing properties that are present
in weight-bearing joints [114], [117]. Proteoglycans also promote the rapid diffusion of nutrients,
metabolites and cytokines by aiding in the hydration of the ECM [118].
Proteoglycans also play a role in chemical signaling between cells. They attach to cell surfaces
and bind to fibrous collagens or fibronectin on the ECM to act in a similar manner to celladhesion molecules [117]. As most proteoglycans are extracellular in nature, they have the
ability to affect signaling cascades and influence intracellular events [119]. Not only do the
molecules function as structural components of the ECM, but they have the ability to sequester
and present many growth factors [117].

2.2.1.4

Glycoproteins

Glycoproteins contain many short, branched oligosaccharide chains and are 1-60% carbohydrate
by weight [97]. For example, fibronectin is an important matrix glycoprotein that it is involved
with cellular adhesion through integrins. In addition, fibronectin is thought to be involved in
directing organization of the ECM [106]. The multi-domain structure of fibronectin plays an
active role in ECM assembly by forming a bridge between cell surface receptors such as
integrins, and collagens, proteoglycans, and other focal adhesion molecules (Figure 2.3c) [115].
Various binding domains present on the fibronectin backbone bind cells as well as molecules
such as fibrin, heparin, and collagens [115]. As another example, laminin is the most abundant
glycoprotein in the basement membrane and is able to bind various receptors on the cell surface
to elicit cellular responses [93]. Laminins are proteins that form sheet-like networks within the
basal lamina of the ECM (Figure 2.3d) [97]. They are known to contribute to the structure of the
ECM and modulate cellular functions such as adhesion, migration, resistance to apoptosis,
stability of phenotype, and differentiation [115].
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2.2.2 Extracellular Matrix-Derived Scaffolding Materials
Cell types may vary widely from one type of tissue to another, but the ECM of various tissues
contains the same base components. Knowing this, research has centralized around the idea of
tissue-engineered biomaterials and scaffolds as a method for synthesizing tissue constructs [6],
[82], [120], [121]. Scaffold design is a major area of research as the scaffold plays an important
role in tissue repair. An ideal 3-D scaffold should mimic the properties of the native tissue but as
this is extremely challenging to achieve, general guidelines for scaffolds include [122]:
(1) The scaffold must promote cell-biomaterial interactions, adhesion, and ECM deposition;
(2) The scaffold must permit transport of gases, nutrients, and regulatory factors as necessary
for cell survival, proliferation, and differentiation;
(3) The scaffold must biodegrade at a controllable rate that approximates the rate of tissue
regeneration under culture conditions of interest;
(4) The scaffold must not elicit a chronic inflammatory response or toxicity in vivo.
Through the use of rationally-designed scaffolds, tissue engineering strategies have demonstrated
the ability to improve tissue repair in vivo [32]. It has been established that the ECM plays a vital
role in the support and regulation of cellular behavior, providing the rationale for using ECM as
a scaffold for tissue repair. In theory, ECM-based biomaterials can meet the above requirements,
and may potentially provide cell-instructive guidance for tissue repair.

2.2.2.1

Tissue-Specific Scaffolds for Tissue Engineering

As it has been previously stated, all tissues have their own tissue-specific composition and
structure that distinguishes them from other tissues within the body. It is this rationale that leads
to the belief that tissue therapies should use materials to mimic the native ECM of that tissue as a
tissue-specific approach is hypothesized to be superior to a non-specific approach [3].
Replicating the ECM of the native tissue for regenerative purposes would require an in-depth
knowledge of the native ECM composition of a particular tissue. Even if replicating the
components was trivial, structural arrangement would still pose a problem that hinders “bottomup” strategies to recapitulate the native microenvironment. As an alternative approach, tissue
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decellularization provides a straightforward method in which tissue samples are treated to
remove cellular components and extract the tissue-specific ECM [82].
Decellularized tissues have been used in their intact form but the lack of a tunable geometry can
pose a potential limitation for some applications [123]. For this reason, the ability to manipulate
the various properties of the scaffolds is an area of significant research interest. The use of
lyophilization and milling to create fine powders and/or enzymatic digestion creates the potential
to manipulate the ECM into desired architectures and formats [1], [124], [125]. Hydrogels,
foams, microcarriers, sheets, powders, and injectable pastes have been developed, with varying
properties including stiffness, porosity, and architecture [1], [126]–[130].
The use of decellularized materials is a promising strategy in tissue engineering. Depending on
processing, the decellularized tissue may provide a complex array of chemical and mechanical
properties through the retention of ultrastructure and signaling proteins that is challenging to
mimic through the use of synthesized biomaterials [18]. This natural, tissue-specific scaffold can
then be used in its intact format or fabricated and manipulated into various forms depending on
the target application [126], [131], [95], [132], [133].

2.3

Tissue Decellularization

Decellularization involves the mechanical, chemical, and/or enzymatic processing of tissues of
the body to remove cellular components while ideally maintaining the structural and functional
integrity of the proteins comprising the ECM. In turn, this will minimize the potential for
immune rejection [82]. Advantages of these methods include that the scaffolds may retain the
native ECM architecture, leading to similar biomechanical properties as seen in vivo. It is also
possible that cell adhesion ligands may still be intact, thereby improving biochemical
interactions [134]. This framework provides a structural lattice for cellular migration and tissue
organization in a way that is difficult to replicate artificially. In the past, decellularization of both
whole organs and tissues has been accomplished [82].
Tissue decellularization has been accomplished by perfusing solutions through existing
vasculature of the tissue, as seen in lung or heart decellularization, or by agitation of tissue
blocks or sections immersed in solutions [18], [19]. While perfusion decellularization may
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provide the advantage of better retaining the original shape/structure of the tissues, this requires
the vascular network of the tissue to be intact. Cannulation is also technically challenging and
may lead to rupture of blood vessels. Not all tissues are extensively vascularized however, and so
immersion and agitation in fluids may be required for proper decellularization. The most
common practices involve the use of acids and bases, hypo- and hypertonic solutions, detergents,
alcohols, enzymes, and mechanical stimulation for decellularization [135].

2.3.1 Chemical Decellularization Methods
Acids and bases are commonly used to either cause or catalyze degradation of biomolecules.
Varying concentrations of acetic acid are commonly used to remove collagens, thereby reducing
ECM strength without disrupting sulphated GAGs [135]. Dermal samples are often subjected to
harsh bases to remove hair in early decellularization. However, treatment with bases is typically
quite harsh and may eliminate growth factors and decrease ECM structural properties by
cleaving collagen fibrils, which is a downside to using bases in decellularization practices [135].
Hypertonic and hypotonic solutions can be most effective when alternated through several cycles
to rinse cell residue from within the tissues following cells lysis [82], [135]. The combination of
the two creates osmotic stress, resulting in cell lysis. Hypotonic saline solutions are used to lyse
cell membranes without causing major changes to the ECM, and can also help to dissociate DNA
from proteins within the cells [82], [136].
Detergents are effective in removing cellular material by solubilizing cell membranes and
dissociating DNA from proteins [135]. While detergents are effective at removing cellular DNA,
they are also known for disrupting and dissociating proteins in the ECM, as evidenced by their
use in proteomics [137], [138]. Detergents can be broadly separated into three categories: (1)
ionic, (2) non-ionic, and (3) zwitterionic [135]. The most commonly used detergents in
decellularization practices are Triton X-100, sodium dodecyl sulphate (SDS) and 3-[(3cholaminopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Triton X-100 (non-ionic)
can be effective at removing cellular residues from some dense tissues, like cartilage. Like
Triton, SDS (anionic) is also widely used for decellularizing thick or dense tissues and has
demonstrated superior removal of cellular DNA when compared to Triton X-100. However, SDS
is also much more disruptive to the ECM and is known to remove important growth factors,
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although the effects may be highly tissue dependent [135]. For this reason, sodium
deoxycholates have been explored as an alternative where retention of ECM growth factors is
important [139], [140]. CHAPS is a zwitterionic detergent that is most effective at removing
cellular material from thin tissues such as lung, while better maintaining the ultrastructure of the
ECM [82], [135]. Care must be taken to remove remaining detergents from tissues, as
cytotoxicity is possible even in small concentrations [20], [135]. Removing anionic detergents
such as SDS can prove to be more difficult than non-ionic detergents [135], [136].
Alcohols such as isopropanol, glycerol, and ethanol dehydrate tissues and lyse cells, making
them useful reagents in decellularization protocols. Alcohols have been shown to remove
intracellular lipids, making them very effective in adipose decellularization protocols [131].
Alcohols are also used as a fixative in histology practices and to precipitate out proteins so
evaluating the effects of alcohols on the ECM is important in order to avoid excess damage to
the ECM [141].
Other solvents such as acetone and tributyl phosphate (TBP) are also used as chemical agents for
decellularization. Acetone can be used to remove lipids, but is also known to produce stiffer
scaffolds by crosslinking the ECM [142]. TBP is an organic solvent that appears to be
particularly good at removing cellular contents from dense tissues, such as tendon [136], [143].
While there have been various reports on the effects it has on the biochemical and mechanical
properties of the ECM, TBP has shown potential as a decellularizing agent over either Triton X100 or SDS in dense tissues for retention of mechanical properties while removing cellular
contents [135], [139], [140].
Enzymes such as trypsin, lipase, collagenase, and various nucleases (RNases and DNases) have
been used in various protocols to disrupt proteins, remove cell residues, and digest nucleic acids
[131], [135]. Enzymes may be used to extract specific components, but use of enzymes alone is
not sufficient for decellularization. Additionally, non-enzymatic agents such as chelators and
serine protease inhibitors are used to aid in cell dissociation from the ECM and minimize ECM
damage. Antibiotics and antimycotics are also used to minimize microbial contamination during
decellularization and are often added to many decellularization solutions [135], [144].
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2.3.2 Mechanical Decellularization Methods
In many cases, mechanical methods must be used in conjunction with chemical decellularization
to achieve effective decellularization. Freeze/thaw cycles are often used to lyse cells within
tissues [135]. Multiple freeze/thaw cycles may be used, with subsequent washes to remove
cellular contents [135]. Some studies have shown that temperature disruption may also reduce
adverse immune responses in vascular ECM scaffolds [145]. Cellular contents can also be
removed through the forces associated with agitation in fluids, gravity separation of lipids
through centrifugation, mechanical abrasion, and tissue compression [131], [95], [135]. These
methods have proven particularly effective, and may cause less disruption to the ECM than
chemical agents. In relatively acellular tissues, such as articular cartilage, freeze/thaw cycles and
pulverizing the tissue through the use of cryogenic milling have been used as the main forms of
decellularization [22], [144]. Limitations of these methods include that freeze/thaw cycles have
limited efficacy on load bearing and mechanically robust tissues, and that pulverizing the tissue
disrupts ECM architecture and has the potential to damage or eliminate important matrix proteins
[133], [146].

2.3.3 Optimizing Methods for Tissue Decellularization
Tissues are comprised of both cellular material and ECM but the physical and chemical bonds
vary in degrees of compactness [82]. The ECM must be adequately disrupted for the cellular
materials to be removed, while minimizing the disruption to the tissue so as to maintain
biomechanical and biochemical components of the ECM. The decellularization process must also
leave the tissue free of added chemicals, such as detergents, if the ECM is to retain the native
composition and limit toxicity in vitro or in vivo [6], [82]. Protease inhibitors may be used to
preserve the ECM during the decellularization process [82], [147].
The specificity of the ECM for each tissue raises the need for unique decellularization practices
with investigation into optimal methods for each tissue. Often, both chemical and mechanical
methods are combined in decellularization protocols to deal with the varying requirements for
tissue-specific decellularization [9], [82]. To test the effectiveness of decellularization, Masson’s
trichrome, DAPI nuclear staining, and DNA quantification, such as using the PicoGreen®
dsDNA assay, are often used to measure cellular remnants. The use of ECM as a cell-instructive
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therapy has been a large area of research in recent years. As such, recent studies have
investigated the results of ASCs seeded on tissue-specific decellularized ECM scaffolds in the
form of intact scaffolds, powders, hydrogels, foams, electrospun fibres and sheets for the
purposes of tissue engineering [32], [38], [125], [148].

2.4

Adipose Tissue

Adipose tissue, derived from pre-adipocytes, is a loose connective tissue found throughout the
body. Its primary role is to act as a regulator of energy metabolism by storing excess energy
taken in through diet [149]. Energy is taken up by the adipose tissue in the form of free fatty
acids (FFAs) with the aid of lipoprotein lipase (LPL). The FFAs are then converted to
triglycerides (TG) within the adipocytes. When the body is in a state of caloric deficit, the stores
of TG are liberated from the adipocytes by lipase in the form of FFAs and glycerol, to be
oxidized and used as energy throughout the body [150], [151]. Due to its role in energy
metabolism, adipose tissue is one of the few organs within the body that is capable of large
changes in mass during adulthood. The typical adult female is approximately 30% fat by body
weight, whereas males are typically around 20% body fat [151].
Adipose tissue is also an important regulator of body temperature and acts to insulate the body
and protect internal organs against mechanical damage [100]. Adipose tissue immediately
surrounding the internal organs is termed ‘visceral fat’, while the anatomical depot underlying
the dermis is considered ‘subcutaneous fat’ [152]. Due to the fact that adipose tissue is highly
vascularized and innervated, it is no surprise that it is also a highly active endocrine organ [153].
Adipose tissue is capable of not only responding to afferent signals, but secreting factors of its
own. Adipokines such as leptin and adiponectin are secreted by this endocrine organ [149],
[153]. Leptin, more commonly known as the ‘satiety signal’, is known for regulating energy
metabolism by regulating appetite [153], [154]. Leptin is released by visceral adipose tissue to
signal the body to stop eating. When energy stores are low, leptin levels are decreased and this
allows the body to feel hunger, acting as a negative feedback loop to regulate food intake [154].
Adiponectin aids in the breakdown of FFAs and assists in controlling blood glucose levels [149],
[100], [155]. Metabolism of sex steroids and glucocorticoids also takes place within adipose
tissue, suggesting that hormones play an important role in the different distributions of body fat
that are present between males and females [149], [153].
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The type of adipose tissue found within adults is termed white adipose tissue. There is another
form of adipose tissue found in infants and young children termed brown adipose tissue [156].
The primary role of brown adipose tissue is to regulate body temperature though heat production
[156]. Brown fat uses a large amount of energy to produce heat in a method called non-shivering
thermogenesis [154]. As people age, brown adipose tissue is replaced by white adipose tissue as
other processes are able to take over temperature regulation [157]. Adipose tissue acquired for
the purposes of cell isolations or decellularization procedures is white adipose tissue.

2.4.1 Adipose ECM Composition
As previously mentioned, the ECM is a complex mixture of proteins, proteoglycans, and
glycoproteins secreted by cells. Adipose tissue ECM also contains a variety of adhesion proteins,
growth factors and cytokines [100]. Integrins connect the ECM to the intracellular cytoskeleton,
which can lead to signaling cascades in response to mechanical stimulation that can spread to
neighboring cells [86]. Cellular cohesion is important in adipose tissue as it is a very dynamic
environment. MMPs enzymatically digest structural components of the ECM to allow for
cellular migration and release of ECM-bound molecules [91].
Collagen makes up a large component of adipose tissue ECM. Adipocytes are surrounded by a
collagen IV-rich matrix that protects the lipid-filled cells from rupturing [101]. The ECM of
adipose tissue is primarily comprised of collagens I, II, III, IV, XII XIV, XV, and XVII, as well
as laminin, fibronectin, elastin, GAGs, and various proteoglycans. Among these, collagen I and
IV are the most abundant [86]. Type I collagen is a fibril-forming collagen with a right-handed
triple helix structure, with two of the α-chains being identical [105]. This is the most prevalent
type of collagen in adipose tissue. As previously discussed, collagen IV is the most abundant
structural component of basal lamina ECM. Collagen IV is a network-type collagen that does not
form fibres, but rather it is arranged into a highly crosslinked mesh [105], [104], which surrounds
the adipocytes, and contains laminins, nidogens, heparin sulphates, and other basement
membrane components [101], [99].
Adipose tissue ECM also includes bioactive components such as GAGs and proteoglycans, as
well as growth factors. GAGs help to keep the tissue hydrated and are often bound to proteins to
form proteoglycans. The most common proteoglycans in adipose tissue are small leucine-rich
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proteoglycans called decorin and biglycan [158], [159]. These proteoglycans can have major
effects on lipid transport/absorption, along with other cellular behaviors [160], [161]. VEGFs
are pro-angiogenic proteins that are present within the ECM, which are secreted by ASCs and
associated with regulating the bioactivity of adipose tissue through signaling for the formation of
new blood vessels [162].

2.4.2 Decellularized Adipose Tissue Scaffolds
Decellularized adipose tissue (DAT) has many applications as a scaffolding material. Building
on the framework of Flynn et al., recent studies have demonstrated the widespread applications
of DAT scaffolds for cell-based therapies [131]. Microcarriers, porous bead foams, foams, and
powders have demonstrated that DAT is adipo-inductive, suggesting that adipogenesis can be
induced by the matrix alone [125], [163]. DAT scaffolds have also shown promise with regards
to promoting angiogenesis in vivo [53].
Generally, adipose decellularization approaches require multiple freeze/thaw cycles in hypotonic
buffers to aid in initial cell lysis, and open up membranes for additional exposure to elements of
decellularization [82], [136], [164]. Enzymatic digestion is also common with the use of
trypsin/EDTA, to disrupt cell-cell adhesion [82]. Subsequent enzymatic treatments with endoand exo-nucleases such as DNase and RNase to remove any remaining nuclear material that may
cause an immunogenic response are common [18]. The use of detergents to ensure sufficient
removal of cellular material from the ECM and disrupt interactions between lipids and proteins is
also a common procedure [82], [131]. Several methods for decellularizing adipose tissue involve
the use of collagenase to break down the tissue, mechanical massaging, and rinses in various
concentrations of SDS, sodium deoxycholate, or Triton X-100, and isopropanol, followed by
lyophilization [165]. However, there is growing evidence to support the notion that detergents
degrade the ECM and if residual detergent remains in the ECM, it can by cytotoxic to cells
[166], [167]. Flynn et al. recognized the importance of developing a uniquely detergent free
decellularization protocol and pioneered new methods to better preserve the native ECM [9].
The Flynn method of decellularization is a 5-day protocol that involves a combination of
freeze/thaw cycles in hypotonic solutions followed by high salt rinses, enzymatic digestion in
trypsin/EDTA and endonucleases, mechanical digestion, and washes in isopropanol [131]. An
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optimized 3-day protocol was also developed that removes the requirement of enzymatic
digestion with DNase and RNase, but continues the use of trypsin/EDTA. Studies to characterize
the resulting ECM have been accomplished, demonstrating that collagen I and IV, laminin,
fibronectin, VEGF-A and adiponectin are retained in the DAT [168].
In the intact form, DAT is an amorphous white substance that when lyophilized, has many
applications. DAT can be used in the intact form, however, the ability to use it as a tunable ECM
source to fabricate varied scaffold designs shows promise for widespread applications in tissue
engineering [46], [131], [165]. Additionally, not many studies have investigated the use of
tissue-specific ECM on adipogenic differentiation, highlighting the need for further research in
this area.

2.5

Cartilage Tissue

Cartilage tissue can be classified into three categories: hyaline (articular) cartilage, elastic
cartilage, and fibrocartilage [169]. Hyaline or articular cartilage is typically found on joint
surfaces, in the bridge of the nose, and trachea. It contains a white, shiny elastic matrix of
various proteoglycans such as aggrecan, chondroitin sulphate, keratin sulphate, biglycan,
fibromodulin, and decorin [170], [171]. Elastic cartilage is found in parts of the larynx but is
most commonly associated with the outer ear. It is more yellow in color and is contained within a
perichondrium. The perichondrium surrounds the surface of most cartilage within the body and is
comprised of a dense, irregular connective tissue [112], [154], [172]. Fibrocartilage is found in
the intervertebral discs, pubic symphasis, and the menisci of the knee [173]. The exception to
this is in the case of injury; the body may remodel damaged articular cartilage into fibrocartilage
during scar formation [174]. Fibrocartilage is the toughest of the three cartilage types as it
consists of dense bundles of collagen fibres and chondrocytes. This tissue does not contain a
perichondrium [175].
It is generally accepted that cartilage has a limited capacity for self-repair due to minimal
vascularity of cartilage tissues and low cell numbers [164]. In general, cartilage is considered to
be both avascular and aneural, except for the small blood vessels and nerves found within the
perichondrium [173], [175], [176]. This greatly increases the need for tissue regeneration
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strategies, particularly for articular cartilages found within joints, and the fibrous cartilage of the
meniscus. These are the two areas that see the most common tissue damage [177].
Articular cartilage functions to protect the surface of the joints and prevent high friction on the
ends of endochondral bone and is the most abundant of the three types of cartilage found within
the body [123]. Type IV collagen can be found within the pericellular region of cartilage, a
distinct region just outside the cell membrane [92]. Cartilage is a dense matrix of collagen II,
aggrecan, and GAGs that are produced by the resident chondrocytes, as outlined in detail in the
next section. These chondrocytes are typically found within spaces called lacunae [172].
Chondrocytes have a rounded or ovoid morphology and are known for secreting large amounts
of matrix, primarily collagen II and various GAGs [178], [179]. The large water and collagen
contents combined with minimal vascularization give the ‘white’ appearance that is often
associated with cartilage [112]. Fibronectin has also been found in the ECM of meniscal
cartilage [175]. Healthy articular cartilage is approximately 70-85% water, allowing for
appropriate joint lubrication at articular surfaces [173], [175]. Cartilage remodeling is a slow
process that involves careful balance of MMPs and tissue inhibitors of metalloproteinases
(TIMPs) [176]. Cartilage is a very dense tissue, with chondrocytes comprising only 5-10% of the
tissue [170], [180]. For this reason, harvesting cells from cartilage yields low cell numbers and
raises the need for cell-based therapies to aid in tissue regeneration [176].

2.5.1 Cartilage ECM Composition
Within cartilage, resident chondrocytes secrete the structural and bioactive molecules that
comprise the ECM. As discussed above, 70-85% of whole cartilage tissue is comprised of water
[123], the majority of which resides within the ECM [173]. Collagens, proteoglycans,
glycoproteins, and small traces of elastin comprise 20-30% of the wet weight of articular
cartilage. Of that 20-30% wet weight, approximately 16% is comprised of collagens [112].
Elastic cartilage is very similar in composition to articular cartilage, except that it contains an
extensive network of elastic fibres [111], [115]. Various assays such as the dimethylmethylene
blue (DMMB) assay or hydroxyproline assay are typically used to estimate GAG or collagen
content respectively [181]–[184].
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Collagen types I – VI, IX, X, and XI have been reported within the ECM of various cartilage
tissues, with collagen type II being the most abundant [173], [185]. Cross-links form between
collagen type II molecules to create collagen fibres. The intramolecular bonds formed create a
strong collagen lattice that gives rise to the tensile properties of cartilage tissue [186]. Within the
cartilage ECM, the high molecular weight proteoglycan aggrecan, which contains chondroitin 4sulphate, chondroitin 6-sulphate, and keratin sulphate, interacts with hyaluronic acid to form
large aggregates that impart resistance to compressive loads [111], [173]. In addition,
chondronectin is an important glycoprotein, as it binds collagens, GAGs, and integrins in order
to mediate chondrocyte adherence in the ECM [111]. Cartilage oligomatrix protein (COMP) is
commonly used as a marker of cartilage turnover and encodes a non-collagenous protein that
aids in cell binding and attachment [187].
Collagens within the ECM have unique fibre orientations that directly contribute to
biomechanical functions and strength. When imaged microscopically, sheets of longitudinally
arranged fibres can be seen in fibrocartilage [188]. The meniscus of the knee has three distinct
layers, each arranged in different directions, which resist tensile stresses placed on the tissue
[113], [175]. Fibrous and hyaline cartilage both have superficial and deep zones. Hyaline
cartilage has an additional intermediate zone and a calcified zone [170], [189], [190]. The
superficial zone protects deeper layers from biomechanical stress and the collagen fibres are
tightly packed in parallel to the articular surface [170]. The intermediate zone is a transitional
zone that contains slightly thicker collagen fibres and more spherical cells. The deep zone,
representing 30% by volume, provides the greatest resistance to compressive forces and contains
collagen fibres that are arranged perpendicular to the articular surface [113], [191]. Within the
deep zone, chondrocytes are typically arranged in columns and show markers of ossification and
hypertrophy as the cartilage is anchored to the bone by collagen fibrils [170].

2.5.2 Decellularized Cartilage Tissue (DCT) Scaffolds
Decellularized cartilage has shown promise in tissue engineering of articular cartilage, menisci,
tracheal cartilage, and temporomandibular joint disc [130], [192]–[195]. Like adipose tissue,
common cartilage decellularization protocols involve the use of multiple freeze/thaw cycles,
rinses in hypotonic buffers, enzymatic digestion, and washes in detergents [21], [22], [143],
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[147]. Commonly used detergents include Triton X-100, SDS, sodium deoxycholate, and TBP.
Although cartilage tissue contains fewer cells than adipose tissue, the dense nature of the tissue
poses a challenge when attempting to extract cellular material. Rinses must occur at higher
agitation to perform proper extraction. Mechanical disruption of the tissue by increasing surface
area is speculated to assist in the decellularization process [1], [127]. There is no standard
decellularization method for cartilage tissue, highlighting the need for studies in this area. After
decellularization, the resulting ECM can be used to create 3-D scaffolds or cell constructs.
To date, approaches have used the intact scaffold such as an ECM plug to promote
chondrogenesis [143], [164]. DCT has also been examined in its powder form as a potentially
injectable ECM source [1]. However, as discussed previously, cartilage is a very dense tissue and
the nature of the ECM makes cell infiltration into decellularized cartilage ECM quite difficult.
Various studies have suggested that the thickness of DCT plays an important role in cell
infiltration, and is therefore a key consideration in cartilage tissue engineering [196]. Gong et al.
attempted to combat this by developing a ‘sandwich model’ where twenty 10 µm- or 30 µmthick articular cartilage sheets were stacked with a 5 L suspension containing 100 ×
106 cells/mL between each sheet and cultured for 16 weeks [130]. The sheets containing 10 µm
slices demonstrated greater collagen staining when compared to the 30 µm sheets. In general,
poor cellular infiltration in cartilage tissue engineering may be combated by using thin sections
of DCT or DCT particles [197], [183], [56]. Some studies have also tried to incorporate in vitro
cell-derived DCT with a polymer such as collagen or alginate as a template [198], [199]. In a
study by Sutherland et al. both cell-derived DCT and devitalized DCT particles demonstrated
upregulation of collagen II and down-regulation of collagen I, X, and RUNX2 [22]. Cell-derived
DCT was composed of cell-secreted matrix from in vitro cultures, whereas devitalized particles
were derived from native tissue. While several different methods of incorporating various types
of DCT into 3-D scaffolds have been explored, the best method for fabricating cell-ECM
constructs for chondrogenesis has yet to be determined [8], [20], [143], [147], [183], [200].
Challenges of using intact DCT scaffolds remain that rigorous decellularization protocols may
lead to greater destruction of the ECM. Additionally, thinner DCT scaffolds may decrease the
biomechanical resilience of the native tissue and may have some unknown effects on
chondrogenesis [200]. There is a great need for studies in the area of cartilage tissue engineering,
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as regeneration remains challenging due to the avascular and aneural nature of the tissue. If
standard methods of cartilage decellularization could be established that minimize damage to the
ECM, DCT scaffolds could represent a promising new cell instructive bioscaffolding platform
for tissue regeneration and/or cell delivery.
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Chapter 3
3

Methods

All chemical reagents for this project were purchased from Sigma-Aldrich Canada Ltd.
(Oakville, Ontario) unless otherwise indicated.

3.1

Objective 1: Tissue Procurement and Decellularization

3.1.1 Adipose Tissue Procurement and Decellularization
Subcutaneous human adipose tissue was obtained with informed consent from patients
undergoing routine breast reduction surgeries at the University Hospital in London, Ontario, with
Research Ethics Board approval from Western University (HREB# 105426). The tissues were
transported to the lab on ice in 10 mM Tris buffer (pH 8.0) within 2 hours of excision.
Cauterized tissue was removed and the remaining adipose tissue was stored in 10 mM Tris buffer
at -80°C. Adipose tissue decellularization was performed using established detergent-free
methods [9]. A working volume of 100 mL was used for all processing steps and all
decellularization solutions were supplemented with 1% (v/v) antibiotic-antimycotic (ABAM)
(Gibco®, Invitrogen, Burlington, Ontario) and 0.27 mM phenylmethylsulfonyl fluoride (PMSF).
In brief, the adipose tissue was subjected to three freeze-thaw cycles in “solution A” comprised
of 10 mM Tris buffer containing 5 mM ethylenediaminetetraacetic acid (EDTA) at pH 8.0. After
the final thawing step, the samples were incubated for 2 hours in fresh solution A under agitation
at 120 RPM and 37°C, and then centrifuged at 1500 x g for 30 minutes. The adipose tissue was
incubated again in solution A for 2 hours, and then transferred into 0.25% trypsin/EDTA
(Gibco®, Invitrogen, Burlington, Ontario) and incubated overnight under agitation at 120 RPM
and 37°C (minimum 8 hours). The following morning, the tissue was incubated in 100%
isopropanol for 3 hours under agitation at 120 RPM and 37°C to extract lipids. Subsequently, the
tissue was compressed with stainless steel filters to enhance lipid separation, placed in 50 mL
conical tubes containing fresh 100% isopropanol, and centrifuged at 1500 x g for 30 minutes.
The isopropanol extraction, mechanical compression, and centrifugation steps were repeated
once before the tissue was incubated in isopropanol under agitation at 120 RPM and 37°C
overnight. The following morning, the sample was manually compressed to remove residual
28

lipid, and incubated in isopropanol for an additional 4 hours under agitation at 37°C. The
decellularized adipose tissue (DAT) was then mechanically compressed once more and
rehydrated in Sorenson’s phosphate buffer (SPB) rinse solution, containing 8 g/L NaCl, 200
mg/L KCl, 1 g/L Na2HPO4, and 200 mg/L KH2PO4 (pH 8.0), through three 30 minute rinses at
37°C under agitation at 120 RPM. The DAT was then rinsed several times in deionized water
(dH2O) prepared with the Barnstead GenPure xCAD Plus system (Thermo Fisher Scientific,
Ottawa, ON, Canada) prior to being lyophilized, as described in section 3.2.1.

3.1.2 Cartilage Tissue Procurement and Decellularization
Porcine ears were obtained from Mount Brydges Abattoir in Mount Brydges, Ontario for use as
an auricular cartilage source. The tissues were transported to the lab on ice within one hour of
sacrifice. To enhance the cartilage surface area in contact with the decellularization reagents, the
dermis was removed with a scalpel and the cartilage was sectioned into small discs using a 5 mm
biopsy punch. The tissue samples were placed in phosphate buffered saline (PBS) and rinsed
three times under agitation at 200 RPM for 10 minutes at room temperature.
Adapting protocols from Xu et al. [136], two decellularization protocols were initially tested. A
solution volume of 50 mL was used and all solutions were supplemented with 1% (v/v) ABAM
and 0.27 mM PMSF. The two protocols were very similar, differing only in the buffer used
during the incubation with deoxyribonuclease (DNase) and ribonuclease (RNase).
First, the tissue samples were subjected to three freeze-thaw cycles in 10 mM tris buffer (pH
8.0). Next, the samples were incubated in a high salt tris buffer containing 1.5 M KCl and 2%
Triton X-100 at 37°C and 200 RPM for 48 hours, with solution changes twice per day.
Subsequently, the tissue was rinsed three times in PBS for 30 minutes each at 37°C under
agitation at 200 RPM. The cartilage was then rinsed in SPB rinse three times for 30 minutes
under agitation at 200 RPM and 37°C. To test two different enzymatic digestion conditions,
cartilage samples were then transferred into one of the following buffers supplemented with 12.5
mg RNase Type III A (from bovine pancreas) and 15,000 U DNase Type II (from bovine
pancreas) for 72 hours under agitation at 200 RPM and 37°C:
Protocol 1A: a 10:1 ratio of PBS to 0.5% trypsin/EDTA
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Protocol 1B: a 10:1 ratio of 50 mM tris buffer to 0.5% trypsin/EDTA
All solutions were replaced twice daily. The enzymatic digestion stage was followed by
incubation in PBS at 37°C and 200 RPM for 24 hours, with the solutions replaced once. The
samples were then incubated at 37°C and 200 RPM in 50 mM Tris buffer (pH 9.0) for 48 hours
and finally, the decellularized cartilage was rinsed several times in PBS and dH2O. The samples
were then prepared for histological analysis, as described in section 3.1.3.
Based on the initial histological results, three different decellularization protocols were
subsequently tested, based on the work of Woods and Grazter [201]. For all three protocols, the
cartilage discs were first subjected to three freeze-thaw cycles in 10 mM tris buffer containing 5
mM EDTA (pH 8.0). The samples were then incubated in a high salt Tris buffer containing 1.5
M KCl and 1% Triton X-100 for 48 hours at 37°C and 200 RPM, with solution changes twice
per day. The samples were then rinsed three times in SPB rinse for 30 minutes under agitation at
200 RPM and 37˚C. Next, the samples were enzymatically digested in Sorenson’s phosphate
buffer digest (SPB Digest) (55 mM Na2HPO4, 17 mM KH2PO4, 4.9 mM MgSO4•7H2O)
supplemented with 12.5 mg RNase Type III A (from bovine pancreas) and 15,000 U DNase
Type II (from bovine pancreas) for 5 hours under agitation at 200 RPM and 37 ˚C. Following
digestion, the tissues were then processed using one of three conditions to extract residual
cellular debris under agitation at 200 RPM and 37 ˚C for 48 hours:
Protocol 2A: 1% tributyl phosphate (TBP) in 50 mM tris buffer
Protocol 2B: 2% Triton X-100 in 50 mM tris buffer
Protocol 2C: 1% sodium deoxycholate (SDC) in 50 mM tris buffer
The decellularized cartilage samples were then rinsed three times in PBS and three times in
dH2O for 30 minutes each, and incubated in 50 mM Tris buffer (pH 9.0) under agitation at 200
RPM and 37 ˚C for 48 hours. Finally, the decellularized cartilage was rinsed several times in
PBS and dH2O and prepared for histological analysis as described in Section 3.1.3.
Based on the results of the second decellularization trial, a slightly modified decellularization
method was tested in which the concentration of Triton X-100 in the initial detergent extraction
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phase was increased from 1% to 2%. This final cartilage decellularization protocol (Protocol 2D)
is summarized in Table 3.1, and was used as the approach for all subsequent experiments.
Table 3.1: Final Cartilage Decellularization Protocol
Day 1







Incubate in high salt Tris buffer containing 1.5 M KCl + 2% Triton
X-100 for 48 hours
Change solutions twice per day






3 x 30 minutes in SPB rinse
Incubate in SPB digest + RNase + DNase for 5 hours
Incubate in 50 mM Tris buffer + 1% TBP for 48 hours
Replace solutions twice per day






3 x 30 minutes in dH20
3 x 30 minutes in PBS
48 hour rinse in 50 mM Tris buffer (pH 9.0)
Replace solutions twice per day




3 x 30 minutes in PBS
3 x 30 minute rinse in 70% ethanol at room temperature under
agitation
3 x 15 minute rinse in sterile PBS at room temperature under
agitation
Store in sterile PBS supplemented with ABAM and PMSF

Days 2-3

Days 4 - 5

Days 6 - 7

Day 8

3 x 15 minute rinse in PBS
Three freeze/thaw cycles in 10 mM Tris buffer containing 5 mM
EDTA (pH 8.0). Replace solutions after each thaw.
Incubate cartilage in 10 mM Tris buffer containing 5 mM EDTA for
24 hours, changing solutions twice




*Note: All processing steps carried out under agitation at 200 RPM and 37˚C, and all solutions
supplemented with 1% ABAM and 0.27 mM PMSF.

3.1.3 Histological Analysis
Processed cartilage samples from the different decellularization trials, along with native porcine
auricular cartilage control samples, were fixed overnight in 4% paraformaldehyde (PFA). The
samples were then rinsed in dH2O, placed in 70% ethanol, and brought to Robarts Molecular
Pathology Laboratory in London, Ontario, for processing. The samples were then embedded in
paraffin and sectioned (7 m sections) using a Leica RM2235 microtome (Leica Biosystems,
Concord, ON, Canada). The sections were deparaffinzed by incubating the slides in xylene for
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10 minutes (2X) and then rehydrated in an ethanol series (100% (2X), 95%, 90%, 80% 70%
EtOH in dH2O for 5 minutes each), followed by dH2O. Masson’s trichrome staining, 0.1 %
safranin O/fast green staining, and DAPI staining using fluoroshield mounting medium
(ab104139, Abcam) were performed to characterize the tissues.

3.2

Objective 2: Milling and Characterization of ECM Particles

Breast adipose tissue from three human donors (N=3) was decellularized and pooled to generate
a DAT stock that was used for all subsequent studies. Similarly, porcine auricular cartilage from
three pigs (N=3) was decellularized and combined to yield a DCT stock. This approach was
undertaken to eliminate batch-to-batch variability in the ECM sources when assessing the effects
of the decellularized ECM on ASC differentiation.

3.2.1 Lyophilization and Cryogenic Milling
The DAT and DCT samples were rinsed in dH2O and frozen at -80°C for 8 hours in 50 mL
conical tubes covered in perforated aluminum foil. The tubes were then transferred on dry ice to
the Labconco Freezone 4.5 lyophilizer (Labconco, Kansas City, MO, United States) and dried
for 48 hours. After lyophilization, the pooled DAT or DCT was finely minced with scissors, and
transferred into a Retsch 25 mL cryo-milling grinding jar. Two thirds of the milling jar was filled
with minced ECM, and two 10 mm stainless steel milling balls were placed in the milling jar.
The cap was tightened, and the jar was immersed in liquid nitrogen for 3 minutes. The tissues
were then milled for 3 minutes at a frequency of 30 Hz using the Retsch Mixer Mill MM 400
milling system. The cycle of immersion in liquid nitrogen and milling were repeated at least once
to obtain a fine powder; during humid weather, additional cycles were required. The particles
were then separated based on size using stainless steel sieves (W.S. Tyler, St. Catharines, ON,
Canada) of decreasing mesh sizes in the following order: 300 μm, 250 μm, 125 μm, and 45 μm.

3.2.2 Particle Size Analysis
Particle size analysis was completed for both the DAT and DCT particles collected between the
45 µm and 125 µm sieves using a Malvern Mastersizer 2000 (Malvern Instruments Ltd.,
Worcestershire, United Kingdom). Approximately 1 g of dehydrated ECM particles was placed
in 500 mL of dH2O with 5 drops of Triton X-100 detergent to disrupt surface tension and reduce
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aggregation of the ECM particles. The samples were then analyzed following the manufacturer’s
instructions. For each pooled ECM source, 3 technical replicates (n=3) were analyzed. The data
was plotted as the mean ± standard deviation (SD). A Kolmogorov–Smirnov test with p < 0.05
was performed using GraphPad Prism 6 (GraphPad Software, San Diego, CA) to assess whether
the particle size distributions for the DAT and DCT particles were statistically equivalent.

3.2.3 Scanning Electron Microscopy
Scanning election microscopy (SEM) was performed on both the DAT and DCT particles
collected between the 45 µm and 125 µm sieves to visualize the ECM ultrastructure after milling
and sieving. Lyophilized, cryo-milled DAT and DCT particles were mounted onto stubs with
conductive carbon tape and coated with 10 nm of osmium before visualization with a LEO 1530
scanning electron microscope. The samples were imaged at 700 and 1000 times magnification
with an accelerating voltage of 1.00 kV and a working distance of 6 mm.

3.3

Objective 3: In vitro cell culture studies

3.3.1 ASC Isolation
Subcutaneous human adipose tissue was obtained with informed consent from patients
undergoing routine breast reduction surgeries at the University Hospital in London, Ontario
(HREB# 105426). Adipose tissue samples were transferred to the lab on ice in PBS
supplemented with 20 mg/mL bovine serum albumin (BSA), and processed within 2 hours of
tissue extraction. Adipose-derived stem/stromal cell (ASC) isolation was performed using
established protocols [202]. Cauterized tissue was removed and the adipose tissue was finely
minced using scissors. The minced adipose was then digested for 45 minutes with 2 mg/mL
collagenase type I (Worthington Biochemical Corporation, Lakewood, NJ, United States) in
sterile Kreb’s Ringer bicarbonate buffer supplemented with 3 mM glucose, 25 mM HEPES and
20 mg/mL BSA at 37°C under agitation at 100 RPM. The digested sample was filtered through a
250 µm stainless steel filter into a 50 mL conical tube, and the mature adipocyte layer was
removed by aspiration following gravity separation. An equal volume of complete medium
comprised of DMEM/Ham’s F12 supplemented with 10% fetal bovine serum (FBS) (Gibco®,
Invitrogen, Burlington, Ontario) and 100 U/mL of penicillin with 0.1 mg/mL streptomycin (penstrep) (Gibco®, Invitrogen, Burlington, Ontario) was added to the sample, which was then
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centrifuged at 1200 x g for 5 minutes. The supernatant was discarded and the pellet was
resuspended in an erythrocyte lysing buffer (0.154 M ammonium chloride, 10 mM potassium
bicarbonate, and 0.1 M EDTA in sterile dH2O) for 10 minutes at room temperature under gentle
agitation. The sample was then centrifuged for 5 minutes at 1200 x g, resuspended in complete
media, filtered through a 100 µm filter, and re-centrifuged. The cell pellet was then resuspended
in complete medium and plated on T-75 culture flasks at a density of 30,000 cells/cm2. The
media was exchanged every 2-3 days. When the cells were at approximately 80% confluence,
they were passaged 1:4 using 0.25% tryspin-EDTA and re-plated in new T-75 culture flasks.

3.3.2 ASC Immunophenotype
The immunophenotype of passage 2 ASCs was analyzed using a Guava® 8HT flow cytometer
(EMD Millipore Corporation, Darmstadt, Germany) following published protocols [152]. Single
marker staining was performed (n=3 technical replicates, N=3 cell donors) with monoclonal,
fluorochrome-conjugated antibodies (eBioscience, San Diego, CA). The positive markers
assessed were CD90, CD44, CD29, CD73, and CD105. CD34 was also analyzed, which is
reported to be expressed in early passage ASCs, but declines with passaging [54]. CD146 was
also analyzed as a marker of pericyte-like cells [54]. The negative markers assessed were CD31
(endothelial) and CD45 (hematopoietic). All trials included controls with unlabeled cells.

3.3.3 Validation of Cell Aggregate Culture Methods
The initial method used to fabricate 3-D cell aggregates involved transferring 1 mL of ASC
suspension at a concentration of 1x106 cells/mL into an uncapped 1.5 mL microcentrifuge tube
positioned inside of a 15 mL vented-cap conical tube, which was then centrifuged at 300 x g for
10 minutes and then maintained in culture for 48 hours [38]. Based on histological analysis using
Masson’s trichrome staining (Figure 3.1), this approach generated non-spherical cell aggregates
that were easily disrupted. As such, an alternate approach was adopted based on the methods of
Gimble et al. [10]. In this strategy, 1 mL of ASC suspension at a lower concentration of 2.5x105
cells/mL was transferred directly into a 15 mL vented-cap conical tube, centrifuged at 300 x g
for 5 minutes and cultured for 48 hours to yield robust spherical cell aggregates (Figure 3.1).
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Figure 3.1 Methods used for generating cell aggregates. (a) 1 million cells cultured in 1.5 mL
microcentrifuge tubes (b) 2.5x105 cells cultured in 15 mL conicals. (scale bars=100 m).

3.3.4 Validation of Chondrogenic Medium Formulation
A pilot study was performed on ASC aggregates generated using the refined approach described
in the previous section to verify that the cells cultured in this configuration could be successfully
induced to express chondrogenic markers when maintained in chondrogenic differentiation
medium for 28 days. The chondrogenic medium formulation was selected based on the work of
Neupane et al. [203], [12] and was comprised of DMEM:Ham’s F12 supplemented with 10%
FBS, 1% pen-strep, 50 μM ascorbate-2-phosphate, 6.25 μg/mL insulin, 100 nM dexamethasone,
and 10 ng/mL TGF-β1 (R&D Systems, CAT#: 100-B-001). For comparison, a second medium
formulation reported by Guilak et al. [71] was also tested, which was comprised of
DMEM:Ham’s F12 supplemented with 10% FBS, 1% pen-strep, 50 μM ascorbate-2-phosphate,
1% ITS+premix supplement (Collaborative Research, CAT#: 40352), 100 nM dexamethasone,
and 10 ng/mL TGF-β3 (R&D Systems, CAT#: 243-B3-010). Non-induced control aggregates
were maintained in complete medium for the duration of the 28-day culture period. To assess
chondrogenic differentiation, cell aggregate samples (n=3) were embedded in OCT and cryosectioned for immunohistochemical (IHC) analysis of collagen II and collagen I expression,
described in detail below. Additional samples (n=3) were fixed in 4% PFA, paraffin-embedded
and sectioned for histological analysis of GAG accumulation by safranin O staining. Native
porcine cartilage was included as a positive control for the IHC and histological analyses.
For IHC analysis, samples were cryo-sectioned (7 µm) with a Leica RM2235 microtome (Leica
Biosystems, Concord, ON, Canada) and collected onto Superfrost® Plus microscope slides
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(Thermo Fisher Scientific, Ottawa, ON, Canada). The sections were warmed at 60˚C for 40
minutes before being transferred to the -20˚C freezer for storage. Immediately prior to staining,
the slides were warmed to room temperature and subjected to antigen retrieval using DAKO
citrate buffer (DAKO, Mississauga, ON, Canada) at 95˚C for 30 minutes, then allowed to cool to
room temperature. The slides were subsequently rinsed in Tris buffered saline (TBS) containing
0.025% Triton X-100, and blocked with 10% goat serum for 1 hour to control for non-specific
binding of the primary antibody. The samples were then incubated in rabbit anti-collagen II
antibody (ab34712, Abcam) diluted to 1:500 in TBS supplemented with 1% BSA solution
overnight at 4˚C, or mouse anti-collagen I antibody (ab90395, Abcam) diluted to 1:500 in TBS
supplemented with 1% BSA for 1 hour at room temperature. Following this, the sections were
rinsed with TBS and incubated in Dylight® 650 goat anti-mouse IgG H&L (ab96882, Abcam)
for collagen I and Dylight® 650 goat anti-rabbit IgG H&L (ab96902, Abcam) for collagen II,
each diluted to 1:500 in TBS supplemented with 1% BSA for one hour at room temperature. The
sections were rinsed, and mounted with mounting medium containing DAPI before imaging with
an Evos FL cell imaging system (Thermo Fisher Scientific, Ottawa, ON, Canada).
To assess GAG accumulation within the pellets by safranin O staining, the paraffin-embedded
and sectioned samples were collected onto Superfrost® Plus microscope slides and
deparaffinized with xylene, followed by rehydration in an ethanol series, and finally to dH20.
The sections were then stained with 0.1% safranin O for 5 minutes before being dehydrated with
95% ethanol for 2 minutes, 100% ethanol for 2 minutes, and cleared in xylene. The slides were
mounted using Permount™ mounting medium (Fisher Scientific, Ottawa, ON, Canada) for
imaging with an Evos XL Core imaging system (Fisher Scientific, Ottawa, ON, Canada).

3.3.5 ASC + ECM Aggregate Formation
Using the milled DAT or DCT particles collected between the 45 µm and 125 µm sieves,
ASC+ECM aggregates comprised of 2.5x105 ASCs and 0.075 mg ECM per aggregate were
fabricated. To fabricate the aggregates, milled DAT or DCT was placed under UV light for 30
minutes before being weighed using a Sartorius CPA225D scale (Sartorius, Bradford, MA,
United States). The milled ECM particles were rehydrated in complete medium at a
concentration of 0.075 mg/mL. 100 µL of the medium containing ECM was transferred into a 15
mL vented-cap conical tube containing 2.5x105 passage 2 ASCs suspended in 900 µL of
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complete medium. The samples were centrifuged at 300 x g for 5 minutes and cultured for 48
hours. Masson’s trichrome staining was performed to confirm that the ECM particles were
successfully integrated into the cell aggregates. To further verify ECM incorporation, a pilot
study was performed in which the DAT and DCT particles were pre-labeled with an aminereactive Alexa fluor 350 succinimidyl ester (Molecular Probes, Burlington, Ontario) prior to
aggregate formation using published methods [127]. At 48 hours, the aggregates were cryosectioned and visualized by fluorescence microscopy, with SYTOX orange nuclear staining.

3.3.6 In vitro Culture Study Design
Detailed in vitro cell culture studies were conducted to explore the effects of the tissue-specific
ECM particles on mediating the lineage-specific differentiation of the ASCs in the 3-D
ASC+ECM aggregate cultures. Table 3.2 summarizes the experimental groups and culture
conditions investigated for the adipogenic and chondrogenic lineages. All experiments were
repeated with passage 2 ASCs sourced from 3 different donors (N=3), using the pooled DAT and
DCT stocks that were previously characterized.
Table 3.2: Summary of Differentiation Studies (N=3 cell donors for each lineage).
Culture
Groups

Adipogenic Differentiation
Time point = 14 days

Chondrogenic Differentiation
Time point = 28 days

DAT+ASCs

Complete Medium

Complete Medium

Adipogenic Medium

Chondrogenic Medium

Complete Medium

Complete Medium

Adipogenic Medium

Chondrogenic Medium

Complete Medium

Complete Medium

Adipogenic Medium

Chondrogenic Medium

DCT+ASCs

ASCs Only
(Control)

For the cell culture studies, ECM+ASC and ASC-alone aggregate samples were cultured for 14
or 28 days in either adipogenic or chondrogenic differentiation medium using the formulations
summarized in Table 3.3. To assess whether the ECM particles or 3-D culture configuration had
any inductive effects on ASC differentiation, non-induced control samples maintained in

37

complete medium were included for all assays, with the exception of the quantitative reversetranscriptase-polymerase chain reaction (RT-qPCR) studies.

Table 3.3 Differentiation Medium Formulations *= only for first 72 hours
Complete Media
DMEM/Ham’s F12
10% FBS
1% pen-strep

Adipogenic Medium [9]
DMEM:Ham’s F12
1% pen-strep
33 μM biotin
17 μM pantothenate
10 μg/mL transferrin
100 nM cortisol
66 nM insulin
1 nM triiodothryonine
0.25 mM
isobutylmethylxanthine *
1 μg/mL troglitazone *

Chondrogenic Medium [12]
DMEM:Ham’s F12
10% FBS
1% pen-strep
50 μM ascorbic acid
6.25 μg/mL insulin
100 nM dexamethasone
10 ng/mL TGF-β1 (R&D
Systems, CAT#: 100-B-001)

3.3.7 Adipogenic Differentiation Study
Adipogenic differentiation was assessed at 14 days by quantitative measurement of glycerol-3phosphate dehydrogenase (GPDH) enzyme activity, IHC analysis to determine the presence of a
hormonally regulated intracellular lipid protein (perilipin), and RT-qPCR analysis of adipogenic
gene expression. As previously discussed, all experiments were repeated with cells isolated from
3 different cell donors (N=3).

3.3.7.1

GPDH Enzyme Activity

GPDH is an enzyme that is upregulated during triglyceride synthesis and its activity can be used
as a quantitative measure of adipogenic differentiation. Following published protocols [152],
intracellular GPDH activity was measured using a spectrophotometric assay with a commercially
available kit (Kamiya Biomedical Company, Tukwila, WA, United States) with normalization to
the total cytosolic protein levels measured using the Bio-Rad protein assay with an albumin
standard (Bio-Rad Laboratories Inc., Hercules, CA). GPDH activity was measured in triplicate
samples for each cell donor (n=3, N=3) at an absorbance of 450 nm using a CLARIOstar®
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spectrophotometer (BMG Labtech, Ortenberg, Germany). The activity required to oxidize 1 µM
of NADH in 1 minute was defined as one unit of GPDH activity.

3.3.7.2

Immunohistochemical Analysis of Perilipin Expression

ECM+ASC and ASC-alone aggregates (n=3, N=3), were fixed in 4% PFA overnight, and
processed at Robart’s Molecular Pathology laboratory. The fixed tissues were embedded in
paraffin, sectioned (7 µm thickness) onto Superfrost® Plus microscope slides (Fisher Scientific,
Ottawa, ON, Canada), and allowed to set overnight at room temperature before use. The sections
were deparaffinized in 100% xylene, followed by rehydration in an ethanol series, and finally
dH2O. The slides were subjected to antigen retrieval using DAKO citrate buffer, rinsed in TBS
containing 0.025% Triton X-100, and blocked with 10% goat serum for 1 hour. The samples
were then incubated in rabbit polyclonal anti-perilipin (ab3526, Abcam) diluted to 1:500 in TBS
with 1% BSA solution overnight. Following this, the sections were rinsed with TBS and
incubated in Dylight® 650 fluorescent goat anti-rabbit IgG secondary antibody (ab96902,
Abcam) diluted to 1 µg/mL in TBS with 1% BSA for one hour at room temperature. The
sections were rinsed, and mounted with DAPI mounting medium for imaging with an Evos FL
cell imaging system (Thermo Fisher Scientific, Ottawa, ON, Canada).

3.3.7.3

RT-qPCR Analysis of Adipogenic Gene Expression

RT-qPCR analysis was performed using TaqMan® Gene Expression Assays to assess the
expression of the adipogenic markers PPAR (Hs00234592_m1), lipoprotein lipase (LPL)
(Hs00173452_m1) and adiponectin (Hs00905917_m1) in the induced samples cultured in
adipogenic differentiation medium for 14 days, with IP08 (Hs00183533_m1) and GAPDH
(Hs02758991_g1) included as the housekeeping genes (based on previous validation in the Flynn
lab). To isolate sufficient RNA, 4 aggregates for each experimental group were pooled together.
For RNA extraction, the pooled aggregate samples were immersed in 1 mL Trizol® Reagent
(Invitrogen, Burlington, Canada), sonicated, and incubated at room temperature for 5 minutes.
200 µL of chloroform (Sigma C7559) was added to the samples, which were vortexed and
incubated at room temperature for 5 minutes, and then centrifuged at 12,000 x g for 15 minutes
at 4°C. The upper aqueous phase was transferred to a new 1.5 mL tube, and an equal volume of
chloroform:isoamyl alcohol (49:1) (Sigma C0549) was added to each tube. The samples were
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vortexed and then centrifuged at 12,000 x g for 15 minutes at 4°C. Once more, the upper aqueous
layer was transferred to a new 1.5 mL tube and an equal volume of 100% isopropanol was
added. The samples were then inverted to mix, incubated at room temperature for 10 minutes,
and centrifuged at 12,000 x g for 10 minutes at 4°C. The supernatant was removed and the RNA
pellet was resuspended in 22 µL of molecular grade water. The concentration and purity of the
RNA was measured using a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific,
Ottawa, ON, Canada).
All samples were subjected to DNase digestion using a TURBO DNA-free kit™ (abmion
AM1907, Life Technologies, Carlsbad, California) following the manufacturer’s instructions.
First strand cDNA synthesis was then performed using the iScript™ kit (Bio-Rad 170-8840,
Mississauga, ON, Canada) following manufacturer protocols with 250 ng of input RNA. Reverse
transcription was carried out in a total reaction volume of 20 µL, consisting of iScript supermix
or no-RT control, and 16 µL of RNA diluted in nuclease-free water. The reaction was carried out
in Bio-Rad C1000 Touch Thermal Cycler (Bio-Rad Laboratories Inc., Hercules, California) with
the following conditions: 5 minutes at 25˚C, 30 minutes at 42˚C, 5 minutes at 85˚C, and then
cooling to 4˚C.
For the PCR amplification, 5 µL of TaqMan® Universal Master Mix II, 3.5 µL of nuclease-free,
molecular grade water, and 0.5 µL of primer were combined in each well. 1 µL of cDNA was
added to each well and the reaction was carried out using a CFX384 Touch™ Real-Time PCR
Detection System (Bio-Rad Laboratories Inc., Hercules, California). The conditions were as
follows: 2 minutes at 50˚C, 20 s at 95˚C, and then 40 cycles of 3 s at 95˚C (denature) and 30 s at
60˚C (anneal/extend). No reverse transcriptase and no template controls were included on every
plate, and all samples were analyzed in triplicate. The results were analyzed using the ∆∆Ct
method [204], with the ASC-alone induced group as the calibrator.

3.3.8 Chondrogenic Differentiation Study
Chondrogenic differentiation was assessed at 28 days by IHC of chondrogenic extracellular
matrix proteins (collagen I and collagen II), histological analysis of GAG accumulation (safranin
o), and RT-qPCR analysis of chondrogenic gene expression. As previously discussed,
experiments were repeated with cells isolated from 3 different cell donors (N=3).
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3.3.8.1

Immunohistochemical Analysis of Collagen II/I Expression

IHC analysis was performed to qualitatively assess the levels of collagen II and collagen I
expression in the ASC+ECM and ASC-alone aggregates (n=3, N=3), following the methods
described in section 3.3.4.

3.3.8.2

Histological Analysis of GAG Accumulation

Safranin O staining was performed to qualitatively assess GAG accumulation in the ASC+ECM
and ASC-alone aggregates (n=2, N=3), following the methods described in section 3.3.4.

3.3.8.3

RT-qPCR Analysis of Chondrogenic Gene Expression

RT-qPCR analysis was performed to assess the expression of the chondrogenic markers SOX9
(Hs0100343_g1), cartilage oligomeric matrix protein (COMP) (Hs00164359_m1), and aggrecan
(Hs00153936_m1) in the induced samples cultured in chondrogenic differentiation medium for
28 days, with UBC (Hs01871556_s1) and RPL13A (Hs04194366_g1) included as the
housekeeping genes (based on previous validation in the Flynn lab). To isolate sufficient RNA, 4
aggregates for each experimental group were pooled together. The samples were analyzed
following the methods for RNA isolation, cDNA synthesis and PCR amplification described in
section 3.3.7.4.

3.3.8.4

Statistical Analysis

Statistical analyses were performed using GraphPad Prism 6 Software by one-way or two-way
ANOVA with Tukey's post-hoc comparison of means. All data values are expressed as a mean ±
standard deviation and significant differences considered when p< 0.05.
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Chapter 4
4

Results and Discussion

4.1

Objective 1: Tissue Procurement and Decellularization

4.1.1 Adipose Tissue Decellularization
Adipose tissue was decellularized using established protocols in the Flynn lab [9]. During
processing, the adipose tissue gradually transitioned into a white, highly-hydrated matrix (Figure
4.1), consistent with previous findings demonstrating effective cell and lipid extraction [9].

Figure 4.1 Macroscopic image of human adipose tissue (a) before and (b) after
decellularization.

4.1.2

Cartilage Tissue Decellularization

Masson’s trichrome and safranin O/fast green staining was performed to compare the tissue
structure and composition (Figure 4.2) following decellularization with two initial cartilage
decellularization protocols adapted from Xu et al. [136]. DAPI staining was used to identify the
presence of residual nuclei in the processed tissues. These protocols, which involved 72 hours
enzymatic extraction with trypsin, DNase and RNase, demonstrated notable changes in the ECM
composition, including qualitatively reduced GAG content, shown in red in the safranin O/fast
green stained sections, with no GAG staining visualized in the samples treated with Protocol 1 B.
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Further, the decellularization processes also appeared to negatively impact the tissue integrity as
the samples were easily torn during sectioning, particularly for those treated with Protocol 1B.
DAPI staining revealed the presence of a large number of residual nuclei in the tissues processed
with Protocol 1A, while no positive nuclear staining was visualized in the samples treated with
Protocol 1B. As the goal was to identify a decellularization protocol that effectively extracted
cellular components while causing minimal changes to the ECM structure and composition,
these findings prompted further investigation into alternative decellularization protocols.

Figure 4.2 Representative histological results of the initial cartilage decellularization
protocols in comparison to native cartilage controls. The first column represents Masson’s
trichrome stains where the cell nuclei appear black and collagen is blue. The second column
represents safranin O/fast green staining. GAGs appear red and collagen appears blue/green. In
the third column, DAPI staining shows cell nuclei in blue. Scale bars represent 100 m.
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Three alternate decellularization protocols based on the work of Woods and Grazter [201] were
tested using TBP or detergent (Figure 4.3), along with a shorter 5-hour DNase and RNase
treatment. From the Masson’s trichrome, safranin O, and DAPI staining, Protocol 2A, comprised
of 1% Triton X-100 treatment followed by 1% TBP extraction (Triton X-100/TBP), showed the
most promising results. The samples processed using this protocol had qualitatively enhanced
GAG staining in comparison to Protocols 1A, 1B, 2B (Triton X-100/Triton X-100) and 2C
(Triton X-100/SDC) and reduced nuclei staining as compared to Protocols 1A and 2B. Relative
to the initial trials, the processed tissues were more robust and easier to handle. Following the
results of the second decellularization trial, a slightly modified approach (Protocol 2D) was
tested using 2% Triton X-100 and 1% TBP to establish if the number of nuclei could be reduced
further by increasing the detergent concentration in the early stages of processing. Masson’s
trichrome and DAPI staining revealed no detectable cell nuclei in the samples processed with
this revised protocol, and demonstrated qualitatively better preservation of the collagen and
GAG content in the ECM relative to the other protocols, with staining patterns similar to native
cartilage. Therefore, based on histological analysis, the decellularization approach in Protocol 2D
was chosen for all future experiments.
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Figure 4.3. Representative histological results of the initial cartilage decellularization
protocols in comparison to native cartilage controls. The first column represents Masson’s
trichrome stains where the cell nuclei appear black and collagen is blue. The second column
represents safranin O/fast green staining (red = GAGs, blue/green = collagen). In the third
column, residual nuclei are shown in blue. Scale bars represent 100 m.
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4.2

Objective 2: Milling and Characterization of ECM Particles

4.2.1 Particle Size Analysis
Lyophilization and cryogenic milling of DAT and DCT yielded a heterogeneous distribution of
particle sizes. The largest yield in terms of the mass of dry particles collected was between the 45
µm and 125 µm sieves (Figure 4.4).

Figure 4.4: Mass of particles generated through cryo-milling DAT or DCT and sorted by
size through sieving. Data presented reflects the results for three pooled donors per ECM
source.
The Mastersizer analysis confirmed that the majority of the particles were in the size range of
less than 125 µm (Figure 4.5). As the particles analyzed with the Mastersizer were in a hydrated
state and prone to agglomeration, the second peak within each trial was suspected to be
associated with particle aggregates. The results of the Kolmogorov–Smirnov test with p < 0.05
confirmed that the particle size distributions for the DAT and DCT particles were statistically
equivalent.
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Figure 4.5 Cryo-milled DAT and DCT particle size distribution analyzed using a laser
diffraction particle size analyzer. The data shown represents the average of three technical
replicates (n=3) of the pooled ECM particles sourced from three donors.

4.2.2 Scanning Electron Microscopy
Based on the SEM images, both the DAT and DCT particles had an amorphous structure with
some visible fibers at the surface (Figure 4.6). However, the images suggest that the DAT and
DCT may have different microstructures that are distinct to each type of tissue. This could
potentially alter cell-ECM interactions with regards to cell attachment, spreading, and
differentiation [205]. Further, structural and compositional variations in the particles may have
some impact on the properties of the cell aggregates with regards to stiffness and cell densities.
However, further research would need to be done to evaluate these potential effects.
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Figure 4.6 Representative SEM images of DAT and DCT particles at 700x and 1000x
magnification.

4.3

Objective 3: In Vitro Cell Culture Studies

4.3.1 Flow Cytometry
Flow cytometry results from three donors (Figure 4.7) demonstrated that the ASCs expressed
markers consistent with the expected ASC immunophenotype. Positive markers CD90, CD44,
CD29, CD73, and CD105 were expressed at high levels (>90%), and the negative markers
CD31, CD45, and CD146 were expressed at levels less than 2%. This is consistent with the
requirements for ASCs as outlined by the International Federation for Adipose Therapeutics
(IFATS) and Science and the International Society for Cellular Therapy (ISCT) guidelines [54].
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Figure 4.7: Representative histograms and average flow cytometry results of ASC marker
expression at passage 1 (n=3, N=3).

4.3.2 Validation of the Chondrogenic Differentiation Medium Formulation
Since chondrogenesis requires close cell-cell contact in order to mimic the condensation process
observed in native tissue formation during development [77], all in vitro culture studies were
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carried out using the self-aggregation methods described in Section 3.3.3. The effects of two
chondrogenic media formulations reported in the literature for inducing chondrogenesis of ASCs
on cartilage ECM production were assessed [12][71]. A qualitatively higher ratio of collagen
II:collagen I expression was observed in the ASC pellets cultured in the differentiation medium
comprised of 89% DMEM/Ham’s F12, 10% FBS, 1% pen-strep, 37.5 µg/mL of ascorbate-2phosphate (A2P), 6.25 µg/mL insulin, 100 ng dexamethasone, and 10 ng/mL TGF-β1. A higher
ratio of collagen II:collagen I is characteristic of cells undergoing chondrogenesis [206], [207].
The safranin O staining also demonstrated qualitatively more uniform and intense staining with
this formulation, suggesting enhanced GAG accumulation (Figure 4.8) indicative of cells
undergoing chondrogenesis. Based on these results indicating effective induction of ASC
chondrogenesis, this chondrogenic medium formulation was used for all subsequent studies.

Figure 4.8 Validation of chondrogenic media formulations. ASC pellets stained for collagen
II and I (red), with DAPI counterstaining (blue), after 28 days in culture (scale bars=100 µm)
(n=2). Safranin O analysis showing GAG content (red) (scale bars=200 µm). Porcine auricular
cartilage was used as a positive control.

50

4.3.3 Verification of ECM Incorporation Within the Cell Aggregates
Masson’s trichrome staining was performed to confirm that the DAT or DCT particles were
successfully integrated into the cell aggregates (Figure 4.9a, b) following the self-aggregation
methods described in Section 3.3.3. It was confirmed that the ECM was incorporated into the
aggregates, with a heterogeneous distribution. To further verify ECM incorporation, a pilot study
was conducted in which the ECM particles were pre-labeled with an amine-reactive Alexa
fluor 350 succinimidyl ester. Visualization with fluorescence microscopy confirmed that the
DAT and DCT particles were heterogeneously incorporated into the aggregates (Figure 4.9c, d).

Figure 4.9 Representative staining of cell-ECM aggregates formed with DAT and DCT
particles. Masson’s trichrome staining of a) DAT + ASC and b) DCT +ASC aggregates
showing embedded ECM particles in dark blue, with examples highlighted with arrows. Scale
bars represent 100 µm. Fluorescence microscopy of Alexa fluor-labeled ECM particles (blue) in
c) DAT+ASC and d) DCT+ASC aggregates with SYTOX® orange (green) nuclear
counterstaining. Scale bars represent 200 µm.
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4.3.4 In Vitro Adipogenic Study
As previously discussed, adipogenesis was assessed using analysis of GPDH enzyme activity,
perilipin by IHC, and adipogenic gene expression by RT-qPCR.

4.3.4.1

GPDH Results

GPDH enzyme activity was measured as a quantitative assessment of adipogenic differentiation.
For ASC donor 1 (age: 41, BMI: 28.8), the GPDH activity levels were quite low and no
significant differences were observed between the groups (Figure 4.10a). It is interesting to note
that this donor had the highest BMI, and previous studies have observed that decreased
adipogenesis has been noted in donors with an increased BMI [41], [152]. Trends indicated that
GPDH activity was higher in the induced groups when compared to the non-induced groups, as
expected. The DAT+ASC induced group demonstrated the highest GPDH activity when
compared to other conditions, suggesting that the DAT may be assisting with the differentiation
toward the adipogenic lineage.
GPDH activity levels for donor 2 (Age:19, BMI: 26.7) were higher, with significantly higher
activity levels observed in the induced conditions as compared to the non-induced conditions for
the DAT+ASC group (Figure 4.10b). The data suggests that incorporating either type of ECM
had a beneficial effect on adipogenic enzyme activity in the 3-D aggregate cultures. Further, the
DAT+ASC induced group showed significantly higher levels of GPDH activity as compared to
all other groups, indicating that adipogenesis was enhanced in the aggregates incorporating the
adipose-derived ECM. Interestingly, significantly higher levels of GPDH enzyme activity were
observed in the DAT+ASC non-induced samples as compared to both ASC-alone conditions,
suggesting that the DAT had an adipo-inductive effect. This is consistent with what has been
reported in the literature, with previous studies demonstrating DAT has the potential to induce
adipogenesis when combined with various culturing methods [9], [53], [125], [148].
Similar to donor 2, GPDH activity was upregulated in donor 3 (Age:40, BMI:23.5) for induced
conditions when compared to the non-induced aggregates within the same group for DAT+ASC
and DCT+ASC conditions. Further, DAT+ASC induced aggregates demonstrated the highest
levels of GPDH activity (Figure 4.10c), which was significantly different than all other groups.
All aggregates incorporating ECM showed increased GPDH activity as compared to the ASC52

alone aggregates, suggesting that the addition of ECM in general, aids in adipogenic
differentiation. In comparing the GPDH levels for the DAT+ASC non-induced group to the
DCT+ASC not induced group and ASC-alone conditions, the findings again suggest that the
adipose ECM had an inductive effect on ASC adipogenic differentiation.

Figure 4.10 GPDH enzyme activity for (a) donor 1, (b) donor 2, and (c) donor 3 at 14 days
after adipogenic induction. DAT = DAT+ASC aggregates, DCT = DCT+ASC aggregates,
ASC = ASC-alone aggregates. I = induced (adipogenic medium), NI = non-induced
(proliferation medium). Data represents the mean  standard deviation (n=3). * indicates
statistically different from all groups (p <0.05). ** indicates statistically different from groups
indicated.

4.3.4.2

Immunohistochemistry

Within mature adipocytes, the lipid droplet-cytoplasm interface is stabilized by the protein
perilipin, which makes perilipin a direct indicator of intracellular lipid accumulation during
adipogenesis [208]. Perilipin in pre-adipocytes will surround cell nuclei, while mature adipocytes
will show positive staining surrounding the nuclei and on the surface of lipid droplets within the
cell cytoplasm [208][150].
Positive perilipin staining was visualized in the DAT+ASC induced condition for donor 1
(Age:17, BMI: 27.5), as well as for the DCT+ASC induced condition. The perilipin staining
demonstrated qualitatively more positive cells in the DAT+ASC induced condition (Figure
4.11a). Moreover, the positive perilipin staining in this group also qualitatively showed that the
cells appear to have a more mature phenotype, with larger intracellular lipid droplets in the cells.
The staining pattern of this donor was most pronounced around the periphery of the aggregates,
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suggesting that the outer cells were undergoing differentiation. It is speculated that nutrient
diffusion may have played a role in this response. More specifically, the outermost cells will
have enhanced access to nutrients and inductive factors in the media as compared to the cells
within the core of the aggregates. This could lead to more bioactive cells at the periphery and
explain the staining patterns seen.
Perilipin was visualized with positive staining in cell donor 2 (Age:19, BMI:26.7) for the
DAT+ASC and DCT+ASC induced conditions. Small rings can be seen around the cell nuclei in
both induced groups incorporating ECM, suggesting that having some type of matrix
incorporated into the aggregates is more beneficial than culturing the cells alone in a 3-D
configuration. The staining was qualitatively more pronounced in the DAT+ASC induced
condition, suggesting that the DAT may be more supportive of adipogenic differentiation than
the DCT (Figure 4.11b).
Interestingly, positive perilipin staining was visualized for all induced conditions for cell donor 3
(Age:49, BMI:23.5), who also had the lowest BMI tested amongst donors. All three induced
conditions had very obvious staining of perilipin positive cells around the exterior of the
aggregates (Figure 4.11c). As discussed previously, it is speculated that this is due to the greater
availability of nutrients and adipogenic supplements at the exterior surface of the aggregates.
Interestingly, the DAT+ASC induced conditions not only demonstrated positive staining around
the exterior of the aggregates, but also within the interior (Figure 4.12). This supports the
previous findings that the DAT particles enhanced ASC adipogenic differentiation.

54

Figure 4.11 Representative IHC images of perilipin expression (red) with DAPI
counterstaining (blue) for (a) donor 1, (b) donor 2, and (c) donor 3. Images shown were
taken at the periphery of the aggregates. Scale bars=100 µm.
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Figure 4.12 Representative IHC images of perilipin expression (red) with DAPI
counterstaining (blue) for donor 3, DAT+ASC induced conditions at (a) 20x magnification
and (b) 40x magnification. Perilipin positive cells were observed in the interior of the cellECM aggregates in this condition. Scale bars are equal to a) 200 µm and b) 100 µm.

4.3.4.3

RT-qPCR Results

Samples from a test run did not yield enough input RNA to allow for measurable readings in the
non-induced conditions. Further, perilipin staining was also negative for the non-induced
conditions, suggesting that intracellular lipid accumulation was minimal when the cells were
maintained in proliferation medium. For these reasons, it was decided to focus the gene
expression analysis on comparing the effects of incorporating the ECM on ASC adipogenesis
under adipogenic differentiation conditions only.
In analyzing the donor 1 samples, a trend of enhanced expression of the early adipogenic marker
PPARϒ was noted in the DAT+ASC induced conditions (Figure 4.13a). Further, the mid-marker
lipoprotein lipase (LPL) and late-marker adiponectin (AdipoQ) were significantly upregulated in
the DAT+ASC conditions when compared to the DCT+ASC and ASC-alone at 14 days. These
results corroborate the GPDH findings that the DAT has instructive effects on promoting ASC
adipogenesis. This is consistent with previous results demonstrating that DAT provides an adipoconductive platform when incorporated into hydrogels and microcarriers [127], [125].
For donor 2 (Age:19, BMI:26.7), PPARϒ expression followed the trend seen with all markers in
that expression was highest in the DAT+ASC induced conditions (Figure 4.13b), and was
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significantly higher than the ASC-alone group. Similar to the GPDH and IHC results, the
expression patterns for all three genes indicated that adipogenic marker expression was enhanced
in the aggregates incorporating ECM. Further, significantly higher levels of LPL and AdipoQ
expression were observed in the DAT+ASC group relative to all other conditions, suggesting
that the adipose ECM enhanced ASC adipogenesis.
While the average fold changes were lower, similar trends were seen for cell donor 3 (Age:49,
BMI:23.5) with regards to gene expression (Figure 4.13c). The aggregates with ECM showed
increased LPL and adiponectin expression when compared to the ASC-alone group, suggesting
that the addition of ECM aids in differentiation. Moreover, significantly higher levels of
expression of these two markers were observed in the DAT+ASC group, indicating that DAT
may be superior to DCT for inducing adipogenic differentiation, and validating what was seen in
both the GPDH enzyme activity assay and perilipin staining.

Figure 4.13 Adipogenic gene expression at 14 days for cell (a) donor 1, (b) donor 2, and (c)
donor 3. Calibrated to ASC induced conditions. DAT = DAT+ASC aggregates, DCT =
DCT+ASC aggregates, ASC = ASC-alone aggregates. I = induced (adipogenic medium). Data
represents the mean  standard deviation (n=3* indicates statistically different from all groups (p
<0.05). ** indicates statistically different from groups indicated.

4.3.5 In Vitro Chondrogenic Study
As previously discussed in Chapter 3, chondrogenesis was assessed using collagen II and
collagen I IHC, safranin O staining of GAG accumulation, and RT-qPCR analysis of
chondrogenic gene expression.
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4.3.5.1

Immunohistochemistry and Histology

It has been suggested in the literature that the proteins collagen I and II are upregulated during
chondrogenesis as extracellular matrix is being produced by the ASCs [206]. An increased ratio
of collagen II:collagen I is expected during chondrogenesis [179].
Results from ASC donor 1 (age: 19, BMI: 26.7) demonstrated (Figure 4.14a) strong positive
staining for collagen II in both DCT+ASC conditions, as well as low levels in the DAT+ASC
and ASC-alone induced groups, suggesting that the cells were undergoing chondrogenesis.
However, a limitation of the experimental design is that it is technically challenging to
distinguish new ECM produced by the cells from the ECM within the embedded particles. Based
on knowledge of the composition of adipose and cartilage ECM, it would be expected that the
DAT particles would be comprised substantially of collagen I and the DCT particles of collagen
II [112]. As such, it is difficult to assess how much of the collagen II in the DCT+ASC groups
was synthesized by differentiating cells. It is worth noting that collagen II staining in the DCT
aggregates was quite uniform, unlike the heterogeneous distribution of the particles in the
aggregates seen in Figure 4.9. Based on the more homogenous staining, it is speculated that at
least part of the collagen II detected was newly synthesized by the cells. IHC showed low levels
of collagen I (Figure 4.15a) expression in all chondrogenic induced conditions, with no
detectable expression in all non-induced controls.
IHC for donor 2 (age:17, BMI: 27.5) demonstrates collagen II accumulation appears to be
enhanced in all conditions when compared to donor 1. Literature suggests that differences in
expression of collagen II and collagen I between trials may be attributed to donor variability
[209]. Collagen II staining was observed in all conditions, with more intense staining found in
the DCT+ASC groups, with a highly uniform staining pattern observed across the entire
aggregate cross-section in the induced conditions (Figure 4.14b). Interestingly, both of the
DAT+ASC groups also showed very uniform collagen II expression, suggesting that the cells
were undergoing chondrogenic differentiation in the presence of the DAT. In contrast, the ASCalone samples had qualitatively reduced collagen II expression in the induced conditions, as well
as no detectable levels of collagen II in the non-induced conditions, suggesting that incorporating
the ECM had a positive effect on ASC chondrogenesis. The collagen I staining results indicate
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that the ASC-alone group cultured in chondrogenic medium had qualitatively enhanced collagen
I expression (Figure 4.15b), consistent with a less differentiated phenotype.
Collagen II staining for donor 3 (age: 50, BMI:29) was more pronounced for all induced
conditions when compared to non-induced counterparts (Figure 4.14c), with the most intense
staining seen in the DCT+ASC aggregates. The DAT+ASC induced group had qualitatively
higher levels of expression as compared to the ASC-alone conditions, further supporting the
previous findings that incorporating the ECM particles had a positive effect on the chondrogenic
differentiation of the ASCs. Interestingly, when magnification was increased to 20X, induced
conditions that included either DAT or DCT showed positive collagen II staining similar to
native cartilage, with evidence of a possible pericellular matrix region around the cells (Figure
4.16). For this cell donor, collagen I was detected in all groups, with qualitatively enhanced
expression in the DCT induced and not induced conditions (Figure 4.15c).
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Figure 4.14 Representative images of collagen II staining (red) with DAPI counterstaining
(blue) from (a) donor 1, (b) donor 2, and (c) donor 3. Scale bars = 100 µm.
60

Figure 4.15 Representative images of collagen I (red) staining with DAPI counterstaining
(blue) from (a) donor 1, (b) donor 2 and, (c) donor 3. Scale bars = 100 µm.
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Figure 4.16 Representative 20X images of collagen II staining with DAPI counterstaining
from donor 3. Induced conditions with (a) native porcine auricular cartilage (b) DAT+ASC and
(c) DCT+ASC groups. Scale bars = 100 µm.
Safranin O staining was used to visualize GAG accumulation within the aggregates (Figure
4.17a). Qualitatively darker staining was observed in the DCT+ASC induced condition than the
other groups cultured in chondrogenic medium, which is suggestive of increased GAG content. It
is worth noting that the aggregates cultured in the induced conditions from all donors were
macroscopically larger than the non-induced controls, suggesting there may be enhanced ECM
deposition in the cultures maintained in chondrogenic medium. This is supported by literature
suggesting that factors such as TGF-β1 and A2P upregulate synthesis of cartilage-specific matrix
containing GAGs and a higher ratio of collagen II:collagen I [78][179].
For donors 2 (Figure 4.17b) and 3 (Figure 4.17c), safranin O staining suggested that induced
conditions displayed consistently more homogenous, darker stains when compared to not
induced conditions. This confirmed what was seen with collagen II and collagen I IHC staining.
DCT+ASC conditions produced more intense and homogenous staining for GAG accumulation
when compared to the DAT+ASC conditions. The combination of data from collagen II/collagen
I IHC and safranin O staining was suggestive of enhanced chondrogenic ECM accumulation in
the DCT+ASC group relative to either DAT+ASCs or ASC-alone.
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Figure 4.17 Representative images of safranin O staining for (a) donor 1, (b) donor 2, and
(c) donor 3. Safranin O staining of GAG content (red) present in cell aggregates. Scale bars =
100 µm.
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4.3.5.2

RT-qPCR Results

To complement the qualitative staining results, RT-qPCR analysis was performed to assess the
expression of the chondrogenic markers SOX9, COMP, and aggrecan in the induced samples
cultured in chondrogenic medium, with UBC and RPL13A included as the housekeeping genes.
The gene expression results showed very consistent patterns across all three donors (Figure
4.18). Results from donor 1 (Figure 4.18a) show a trend for enhanced SOX9 gene expression and
significantly higher levels of AGG gene expression in the DCT+ASC experimental group as
compared to the other two groups. Interestingly, the DAT+ASC group demonstrated significant
upregulation of the COMP gene as compared to the other conditions. One possibility is that
COMP gene expression may have peaked earlier in the DCT+ASC group when compared to the
DAT+ASC conditions, causing the results seen. A similar study saw chondrogenic genes
upregulated after one week in studies combining decellularized cartilage with bone-marrowderived stem cells (bMSCs) [210]. While RT-qPCR quantitatively measures gene expression, it
only provides information about the levels of gene expression at the point in time when the
samples were processed. Given that gene expression patterns can vary considerably as
differentiation progresses, average fold changes would very likely be different if the samples
were assessed at an earlier or later time point. Since COMP has been reported as an early/mid
marker and AGG as a late-stage marker of human mesenchymal stem cell (MSC)
chondrogenesis [211], it is possible that the DCT+ASC group had a more differentiated
phenotype, although further studies with additional time points and markers would be required to
verify this interpretation.
While the average fold change values were generally higher, in comparing the groups, the gene
expression patterns for donor 2 were very similar to donor 1. DAT induced conditions for donor
2 (Figure 4.18b) show a trend of enhanced SOX9 expression in both groups that incorporate
ECM. Two-way ANOVA results indicate significantly elevated COMP expression in the
DAT+ASC group relative to all other conditions, as well as in the DCT+ASC group as compared
to the ASC-alone samples. Additionally, similar to donor 1, AGG was significantly upregulated
in the DCT+ASC aggregates when compared to both the DAT+ASC and ASC-alone groups.
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Results from the RT-qPCR analysis for donor 3 (Figure 4.18c) were very similar to those of
donor 1. Again, trends indicated enhanced SOX9 expression in the DCT+ASC group. Similar to
the other donors, results indicated that the DAT+ASC group showed elevated COMP expression
when compared to the DCT+ASC and ASC-alone groups, and that the DCT+ASC group had
enhanced COMP expression when compared to the ASC-alone group. This suggests that the
addition of ECM is superior to ASC-alone for promoting chondrogenic differentiation.
Moreover, AGG gene expression was again significantly enhanced in the DCT+ASC group,
potentially suggestive of a more differentiated phenotype.

Figure 4.18 Chondrogenic gene expression at 28 days for (a) cell donor 1, (b) donor 2 and,
(c) donor 3. Calibrated to ASC induced conditions. DAT = DAT+ASC aggregates, DCT =
DCT+ASC aggregates, ASC = ASC-alone aggregates. I = induced (adipogenic medium).
Data represents the mean  standard deviation (n=3). * indicates statistically different from
all groups (p <0.05). ** indicates statistically different from groups indicated.
Results and trends from this study suggest that incorporating ECM promotes chondrogenic gene
expression relative to ASC-alone, which is consistent with the IHC staining results. A limitation
of this study is that only one time point was analyzed. As discussed, it would be interesting to
look at a time series in future studies to analyze changes in gene expression among the different
conditions. The COMP protein plays an important role in growth, division, cell attachment, and
apoptosis in cartilage tissue [72]. This non-collagenous protein has been shown to interact with
SOX9 to promote chondrogenic activity of MSCs from cellular condensation to terminal
differentiation [72], [211]. COMP is upregulated in chondroprogenitors through to terminal
differentiation [72], while AGG is typically regarded as a mature chondrocyte matrix gene [212].
One study showed that COMP levels in human MSCs induced to differentiate in 3-D alginate
gels peaked around 12 days, while AGG levels peaked beyond 24 days, raising the need for a
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time series including time points at 7 and 14 days [211]. Additionally, other late expression
markers such as lubricin (PRG4) and matrilin-1, as well as the hypertrophic marker collagen X,
could be assessed at 28 days to corroborate the speculations made above.
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Chapter 5
5

Conclusions

As the emerging field of tissue engineering and regenerative medicine continues to expand upon
the knowledge of the extracellular matrix (ECM), it becomes apparent that there is greater need
for tissue-specific cell-based therapies. Tissues such as cartilage have a limited regenerative
capacity and require assistance in order to return functionality back to the tissue. Each tissue
within the body has a specific structure and function, providing a rationale for the use of tissuespecific scaffolds for regenerative purposes. While research has investigated the effects of tissuespecific biomaterials and scaffolds on differentiation, few studies to date have focused on the
effects of multiple ECM sources on directing the lineage-specific differentiation of stem cells
[8], [148]. This begs the question, do tissues require a specific ECM or will the addition of any
type of ECM aid in the differentiation of stem/stromal cells? Incorporating decellularized ECM
sourced from adipose tissue or cartilage into cell aggregate cultures provides insight into the
potential importance of using tissue-specific ECM to guide differentiation and/or to act as a
natural scaffold for the regeneration of adipose or cartilage tissue. Decellularized matrices
represent an attractive biomaterial for 3-D scaffolds because they retain a complex mixture of
functional and structural proteins from natural tissue sources [82].
Detergent-free methods of decellularization had been previously established in order to fabricate
decellularized adipose tissue (DAT). In order to examine the effects of DAT and decellularized
cartilage tissue (DCT), an examination of various cartilage decellularization protocols based on
the literature was required. Successful decellularization of the ECM required removal of cellular
materials while maintaining the integrity of the native tissue. Several different protocols were
tested. A protocol was developed that successfully removed cellular material while
macroscopically preserving the collagen and GAG within the ECM, which involved: repeated
freeze/thaw cycles, osmotic cell lysis through washes in hypotonic Tris buffers, 5-hour
enzymatic digestion with trypsin/EDTA, and rinses in a high salt buffer containing 2% Triton X100, followed by 1% tributyl-phosphate (TBP). Successful decellularization of cartilage was
achieved through removal of cellular contents as visualized by Masson’s trichrome and DAPI
staining. GAG retention was also qualitatively maintained through the use of this protocol.
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DAT and DCT were lyophilized and milled into ECM particles. The particles were then sorted
by size, collecting those captured between 45 µm and 125 µm screens. The resulting particles
were characterized using dynamic light scattering and scanning electron microscopy. It was
concluded that a heterogeneous mixture of particle sizes was achieved through the process, with
some structural differences noted between the two types of ECM.
Finally, in vitro culture studies were conducted to assess the potential effects of the tissuespecific ECM on the lineage-specific differentiation of human adipose-derived stem/stromal cells
(ASCs). First, chondrogenic media formulations were tested and culture methods were
established for creating the cell-ECM aggregates. Subsequently, in vitro cell culture studies were
conducted to investigate adipogenesis and chondrogenesis of aggregates comprised of (i)
DAT+ASCs, (ii) DCT+ASCs, and (iii) ASC-alone, cultured in both differentiation and
proliferation media.
The results demonstrated that the addition of ECM generally improved differentiation for both
adipogenesis and chondrogenesis, as demonstrated by analysis of protein expression and
confirmed with RT-qPCR. Both adipogenic and chondrogenic markers were upregulated in
conditions containing ECM when compared to the ASC-alone groups.
Adipogenesis was assessed by glycerol-3-phosphate dehydrogenase (GPDH) activity, perilipin
immunohistochemistry (IHC) and RT-qPCR. The GPDH results consistently demonstrated that
GPDH expression was higher in all induced aggregates when compared to the corresponding
non-induced controls. The DAT+ASC groups consistently showed the highest levels of GPDH
activity, suggesting that incorporating the DAT enhanced adipogenesis relative to either the
DCT+ASCs or ASC-alone. Perilipin results confirmed this finding, as the DAT induced
conditions consistently stained positive for perilipin, with the cells qualitatively having a more
mature phenotype associated with larger intracellular lipid droplets. For the third cell donor,
positive perilipin staining was visualized around the edges of the aggregates for all induced
conditions. However, the DAT induced aggregates were the only group that also demonstrated
perilipin staining within the interior of the aggregates in this set of samples. RT-qPCR results
consistently demonstrated that the DAT+ASC induced conditions had larger fold changes for the
adipogenic markers LPL and adiponectin. Taken together, the findings support that the DAT has
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adipo-inductive and adipo-conductive properties and is superior to either the DCT or ASCs alone
for inducing adipogenesis within 3-D aggregate cultures.
Chondrogenesis was assessed by comparing collagen II and collagen I expression, as higher
expression of collagen II is related to increased chondrogenic activity. A limitation of this study
was that it was difficult to discern newly synthesized matrix from the ECM in the particles that
were incorporated into the aggregates. IHC results demonstrated once again that the inclusion of
ECM had a positive effect on differentiation relative to culturing the ASCs alone. The
DCT+ASC samples consistently demonstrated more intense fluorescent staining for collagen II
than the other conditions, but as mentioned previously, it was difficult to differentiate between
the ECM particles and newly-synthesized matrix within the aggregates. Safranin O staining
demonstrated darker staining in all induced conditions, and when combined with the IHC results,
supported the conclusion that incorporating either type of ECM in the aggregates enhanced
cartilage matrix synthesis. The uniformity of the response may suggest that incorporating DCT
may be superior to DAT in terms of collagen II/collagen I production, but further studies would
be required to verify this interpretation. Results of RT-qPCR studies showed trends that the
DCT+ASC group had enhanced SOX9 expression at 28 days when compared to the other
groups. Further, RT-qPCR results for all three donors show that COMP gene expression was
upregulated for both the DAT+ASC and DCT+ASC groups when compared to ASC-alone at 28days, with significantly higher expression in the DAT+ASC group. Additional time points may
demonstrate different results at 7 and 14 days, as several studies have seen SOX9 and COMP
levels peak between 6 and 14 days [1], [211]. Additionally, all donors demonstrated that AGG
gene expression was upregulated in DCT+ASCs when compared to either DAT+ASCs or ASCalone, and supports the theory that the DCT+ASC aggregates may be more terminally
differentiated than other groups. Additional gene expression studies would help to confirm this
hypothesis.
Towards the development of tissue-specific cell-based strategies for tissue engineering, the data
obtained highlights the potential effects that the ECM has on the differentiation of ASCs and
demonstrates a promising use of decellularized ECM materials for the development of tissuespecific instructive platforms for directing mesenchymal stem/stromal cell (MSC) differentiation.
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5.1

Future Recommendations

Short-term goals to build from the work presented in this thesis include further application of
fluorescent labeling of the DAT and DCT particles prior to incorporation in the cell-ECM
aggregates to assist in distinguishing the newly-synthesized ECM from the ECM particles during
IHC analyses. This would give a better indication of collagen II and collagen I production,
particularly in the DCT+ASC conditions. It would also be interesting to look at chondrogenic
differentiation at earlier time points of 7 and 14 days to see how gene expression changes in the
earlier stages of chondrogenesis. One study showed increased gene expression levels in cellECM aggregates incorporating DCT at 24 hours and 7 days [1]. It would also be beneficial to
look at wider array of chondrogenic genes such as SOX5, SOX6, COLII, lubricin, matrilin-1 and
COLX. A more quantitative assay such as the Blyscan™ sulphated GAG assay kit or DMMB
assay could also be done to give more quantitative results to complement the safranin O staining.
It would also be worthwhile to repeat the adipogenic studies to further validate trends with
additional cell donors. This would clarify the results of this study and may provide more insight
into whether there are differences between the aggregates incorporating DAT and DCT.
Porcine auricular cartilage was used as an ECM source for this study as a proof of concept. It
would be interesting to examine a different cartilage source, such as fibrocartilage or hyaline
cartilage, to see if the tissue source has an impact on the chondrogenic differentiation of the
ASCs. Additionally, it would be worth exploring human cartilage as a source of DCT, although
this would be more challenging to obtain. Expanding on the overall strategy for this project, it
would be worth examining decellularization of other tissues such as bone, skin, and muscle.
Using similar methods, ASCs and ECM could be combined and differentiated towards the
osteogenic, endothelial, and myogenic lineages in order to gain a broader understanding of the
potential effects of tissue-specific ECM.
Alternatively, it would be interesting to investigate the manipulation of the DCT as a scaffolding
material. If the DCT were enzymatically digested, this could allow for the fabrication of ECMdervied foams, microcarriers, and sheets. These alternative scaffold formats would allow for
better control of the architecture of the scaffold and potentially better control of the distribution
of ECM compared to the cells. This was a limitation in this project that could be addressed
through the manipulation of the ECM materials. More specifically, it was difficult to control the
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distribution of the ECM and the cells, leading to heterogeneous cell-ECM aggregates. Using
ECM-derived microcarriers, for example, might solve this problem, and would still allow for the
3-D culture conditions required for chondrogenesis. The porosity could also be controlled, which
may aid in cell infiltration into the scaffold, which is a common problem with current cartilage
tissue engineering methods [123].
In terms of long-term goals for the work presented in this thesis, incorporating the ECM particles
into other materials, such as hydrogels would be an interesting way to examine the effects the
ECM has on differentiation where nutrient availability could be limited. Some recent studies
have suggested that ECM-derived materials can provide an instructive microenvironment for
directing stem/stromal cell fate [8], [192]. ECM particles could also be incorporated into
injectables, to develop clinically-translational cell-based therapies using the ECM as an
instructive component to direct stem cell differentiation. Testing these results with various
decellularized tissues to examine the tissue-specific effects could be first accomplished in vitro.
In terms of in vivo work, murine models can be used to examine the effects of tissue-specific
cell-ECM therapies. Incorporating various scaffold types into different tissues can aid in the
understanding of how the ECM can affect cellular fate in vivo. Additionally, it should be
proposed that cell-based therapies continue to incorporate naturally-derived ECM into
experiments, as this has shown promise for aiding the proliferation and differentiation of
stem/stromal cells both in vitro and in vivo.
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Appendix A

Figure A.1: Immunohistochemical of collagen II and collagen I (red) staining with DAPI
counterstaining (blue) on (a) porcine cartilage (COL II) and skin (COL I) and, (b) with no
primary controls. Scale bars = 100 µm (n=2).
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Figure A 2: Immunohistochemical of perilipin (red) staining with DAPI counterstaining
(blue) on (a) murine adipose tissue and, (b) with no primary controls. Scale bars = 100 µm
(n=2).
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